{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T21:40:00Z","timestamp":1793742000612,"version":"4.6.1"},"reference-count":363,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,28]],"date-time":"2023-10-28T00:00:00Z","timestamp":1698451200000},"content-version":"am","delay-in-days":331,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01GM143217"],"award-info":[{"award-number":["R01GM143217"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R03CA262490"],"award-info":[{"award-number":["R03CA262490"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology &amp; Therapeutics"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.pharmthera.2022.108300","type":"journal-article","created":{"date-parts":[[2022,10,22]],"date-time":"2022-10-22T11:33:01Z","timestamp":1666438381000},"page":"108300","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"special_numbering":"C","title":["Nucleoside transporters and immunosuppressive adenosine signaling in the tumor microenvironment: Potential therapeutic opportunities"],"prefix":"10.1016","volume":"240","author":[{"given":"Tejinder","family":"Kaur","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brenna","family":"Weadick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas A.","family":"Mace","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kajal","family":"Desai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Odom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajgopal","family":"Govindarajan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pharmthera.2022.108300_bb0005","doi-asserted-by":"crossref","first-page":"251","DOI":"10.3892\/ol.2021.12512","article-title":"Dipyridamole induces the phosphorylation of CREB to promote cancer cell proliferation","volume":"21","author":"Abdelghany","year":"2021","journal-title":"Oncology Letters"},{"key":"10.1016\/j.pharmthera.2022.108300_bb0010","doi-asserted-by":"crossref","first-page":"877","DOI":"10.2217\/pgs.15.44","article-title":"RNA expression of genes involved in cytarabine metabolism and transport predicts cytarabine response in acute myeloid leukemia","volume":"16","author":"Abraham","year":"2015","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.pharmthera.2022.108300_bb0015","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1084\/jem.20151193","article-title":"Tumor macrophages are pivotal constructors of tumor collagenous matrix","volume":"213","author":"Afik","year":"2016","journal-title":"The Journal of Experimental Medicine"},{"key":"10.1016\/j.pharmthera.2022.108300_bb0020","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/j.bbamem.2010.05.016","article-title":"The resurgence of A2B adenosine receptor signaling","volume":"1808","author":"Aherne","year":"2011","journal-title":"Biochimica et Biophysica Acta"},{"key":"10.1016\/j.pharmthera.2022.108300_bb0025","doi-asserted-by":"crossref","DOI":"10.3390\/cells9081914","article-title":"Decreased equilibrative nucleoside transporter 1 (ent1) activity contributes to the high extracellular adenosine levels in mesenchymal glioblastoma stem-like cells","volume":"9","author":"Alarcon","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.pharmthera.2022.108300_bb0030","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/icb.2017.8","article-title":"Targeting A2 adenosine receptors in cancer","volume":"95","author":"Allard","year":"2017","journal-title":"Immunology and Cell Biology"},{"key":"10.1016\/j.pharmthera.2022.108300_bb0035","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/S0306-4522(03)00523-2","article-title":"Purinergic P2 receptors trigger adenosine release leading to adenosine A2A receptor activation and facilitation of long-term potentiation in rat hippocampal slices","volume":"122","author":"Almeida","year":"2003","journal-title":"Neuroscience"},{"key":"10.1016\/j.pharmthera.2022.108300_bb0040","first-page":"350","article-title":"Potentiation of chemotherapeutics by bromelain and N-acetylcysteine: Sequential and combination therapy of gastrointestinal cancer cells","volume":"6","author":"Amini","year":"2016","journal-title":"American Journal of Cancer Research"},{"key":"10.1016\/j.pharmthera.2022.108300_bb0045","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1046\/j.1471-4159.1999.0730867.x","article-title":"Distribution of equilibrative, nitrobenzylthioinosine-sensitive nucleoside transporters (ENT1) in brain","volume":"73","author":"Anderson","year":"1999","journal-title":"Journal of Neurochemistry"},{"key":"10.1016\/j.pharmthera.2022.108300_bb0050","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1002\/ibd.20316","article-title":"Pharmacological modulation of adenosine system: Novel options for treatment of inflammatory bowel diseases","volume":"14","author":"Antonioli","year":"2008","journal-title":"Inflammatory Bowel Diseases"},{"key":"10.1016\/j.pharmthera.2022.108300_bb0055","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.pharmthera.2008.08.010","article-title":"Regulation of enteric functions by adenosine: Pathophysiological and pharmacological implications","volume":"120","author":"Antonioli","year":"2008","journal-title":"Pharmacology & Therapeutics"},{"key":"10.1016\/j.pharmthera.2022.108300_bb0060","doi-asserted-by":"crossref","first-page":"3868","DOI":"10.1111\/bph.12748","article-title":"Nucleoside transporters and human organic cation transporter 1 determine the cellular handling of DNA-methyltransferase inhibitors","volume":"171","author":"Arimany-Nardi","year":"2014","journal-title":"British Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2022.108300_bb0065","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1177\/1074248413511693","article-title":"Characterization of the adenosine pharmacology of ticagrelor reveals therapeutically relevant inhibition of equilibrative nucleoside transporter 1","volume":"19","author":"Armstrong","year":"2014","journal-title":"Journal of Cardiovascular Pharmacology and Therapeutics"},{"key":"10.1016\/j.pharmthera.2022.108300_bb0070","first-page":"2933","article-title":"Synthesis, characterization, and evaluation of poly (D,L-lactide-co-glycolide)-based nanoformulation of miRNA-150: Potential implications for pancreatic cancer therapy","volume":"9","author":"Arora","year":"2014","journal-title":"International Journal of Nanomedicine"},{"key":"10.1016\/j.pharmthera.2022.108300_bb0075","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/j.nano.2011.03.009","article-title":"Enhanced antiproliferative activity of Herceptin (HER2)-conjugated gemcitabine-loaded chitosan nanoparticle in pancreatic cancer therapy","volume":"7","author":"Arya","year":"2011","journal-title":"Nanomedicine"},{"key":"10.1016\/j.pharmthera.2022.108300_bb0080","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1002\/jcp.25050","article-title":"Dual Effect of Adenosine A1 Receptor Activation on Renal O2 Consumption","volume":"230","author":"Babich","year":"2015","journal-title":"Journal of Cellular Physiology"},{"key":"10.1016\/j.pharmthera.2022.108300_bb0085","doi-asserted-by":"crossref","first-page":"15880","DOI":"10.1074\/jbc.M414337200","article-title":"Functional characterization of novel human and mouse equilibrative nucleoside transporters (hENT3 and mENT3) located in intracellular membranes","volume":"280","author":"Baldwin","year":"2005","journal-title":"The Journal of Biological Chemistry"},{"key":"10.1016\/j.pharmthera.2022.108300_bb0090","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1161\/01.RES.0000238359.18495.42","article-title":"Distribution and functional characterization of equilibrative nucleoside transporter-4, a novel cardiac adenosine transporter activated at acidic pH","volume":"99","author":"Barnes","year":"2006","journal-title":"Circulation Research"},{"key":"10.1016\/j.pharmthera.2022.108300_bb0095","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1172\/JCI89455","article-title":"Targeting the adenosine 2A receptor enhances chimeric antigen receptor T cell efficacy","volume":"127","author":"Beavis","year":"2017","journal-title":"The Journal of Clinical Investigation"},{"key":"10.1016\/j.pharmthera.2022.108300_bb0100","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1158\/0008-5472.CAN-10-2736","article-title":"CNT1 expression influences proliferation and chemosensitivity in drug-resistant pancreatic cancer cells","volume":"71","author":"Bhutia","year":"2011","journal-title":"Cancer Research"},{"key":"10.1016\/j.pharmthera.2022.108300_bb0105","doi-asserted-by":"crossref","first-page":"238","DOI":"10.2174\/157015909789152182","article-title":"Adenosine and sleep","volume":"7","author":"Bjorness","year":"2009","journal-title":"Current Neuropharmacology"},{"key":"10.1016\/j.pharmthera.2022.108300_bb0110","first-page":"2602","article-title":"The extracellular fluid of solid carcinomas contains immunosuppressive concentrations of adenosine","volume":"57","author":"Blay","year":"1997","journal-title":"Cancer Research"},{"key":"10.1016\/j.pharmthera.2022.108300_bb0115","doi-asserted-by":"crossref","first-page":"7505","DOI":"10.1007\/s00018-021-03959-8","article-title":"OncomiRs miR-106a and miR-17 negatively regulate the nucleoside-derived drug transporter hCNT1","volume":"78","author":"Boces-Pascual","year":"2021","journal-title":"Cellular and Molecular Life Sciences"},{"key":"10.1016\/j.pharmthera.2022.108300_bb0120","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1007\/s00280-011-1716-7","article-title":"Nucleoside transporters are widely expressed in ovarian carcinoma effusions","volume":"69","author":"Bock","year":"2012","journal-title":"Cancer Chemotherapy and Pharmacology"},{"key":"10.1016\/j.pharmthera.2022.108300_bb0125","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s000110050341","article-title":"Increased release of ATP from endothelial cells during acute inflammation","volume":"47","author":"Bodin","year":"1998","journal-title":"Inflammation Research"},{"key":"10.1016\/j.pharmthera.2022.108300_bb0130","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/j.1476-5381.1994.tb13043.x","article-title":"Studies of the nucleoside transporter inhibitor, draflazine, in the human myocardium","volume":"112","author":"Bohm","year":"1994","journal-title":"British Journal of Pharmacology"},{"issue":"Suppl. 6","key":"10.1016\/j.pharmthera.2022.108300_bb0135","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/epi.12268","article-title":"Role of adenosine in status epilepticus: A potential new target?","volume":"54","author":"Boison","year":"2013","journal-title":"Epilepsia"},{"key":"10.1016\/j.pharmthera.2022.108300_bb0140","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.ccell.2019.10.007","article-title":"Adenosine metabolism: Emerging concepts for cancer therapy","volume":"36","author":"Boison","year":"2019","journal-title":"Cancer Cell"},{"key":"10.1016\/j.pharmthera.2022.108300_bb0145","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1016\/j.ejca.2011.11.006","article-title":"Human equilibrative nucleoside transporter 1 (hENT1) expression is a potential predictive tool for response to gemcitabine in patients with advanced cholangiocarcinoma","volume":"48","author":"Borbath","year":"2012","journal-title":"European Journal of Cancer"},{"key":"10.1016\/j.pharmthera.2022.108300_bb0150","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/978-3-540-89615-9_10","article-title":"A3 adenosine receptor: Pharmacology and role in disease","author":"Borea","year":"2009","journal-title":"Handbook of Experimental Pharmacology"},{"key":"10.1016\/j.pharmthera.2022.108300_bb0155","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1080\/15257770.2016.1210805","article-title":"Equilibrative nucleoside transporters-A review","volume":"36","author":"Boswell-Casteel","year":"2017","journal-title":"Nucleosides, Nucleotides & Nucleic Acids"},{"key":"10.1016\/j.pharmthera.2022.108300_bb0160","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1126\/science.278.5335.124","article-title":"Maintenance of human T cell anergy: Blocking of IL-2 gene transcription by activated Rap1","volume":"278","author":"Boussiotis","year":"1997","journal-title":"Science"},{"key":"10.1016\/j.pharmthera.2022.108300_bb0165","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1097\/00001813-200201000-00003","article-title":"Nucleoside transport inhibitors, dipyridamole and p-nitrobenzylthioinosine, selectively potentiate the antitumor activity of NB1011","volume":"13","author":"Boyer","year":"2002","journal-title":"Anti-Cancer Drugs"},{"key":"10.1016\/j.pharmthera.2022.108300_bb0170","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1038\/nm1000","article-title":"PKC-alpha regulates cardiac contractility and propensity toward heart failure","volume":"10","author":"Braz","year":"2004","journal-title":"Nature Medicine"},{"key":"10.1016\/j.pharmthera.2022.108300_bb0175","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/9780470032244.ch4","article-title":"Purinergic signalling--an overview","volume":"276","author":"Burnstock","year":"2006","journal-title":"Novartis Foundation Symposium"},{"key":"10.1016\/j.pharmthera.2022.108300_bb0180","doi-asserted-by":"crossref","first-page":"661","DOI":"10.3389\/fphar.2017.00661","article-title":"Purinergic signalling: Therapeutic developments","volume":"8","author":"Burnstock","year":"2017","journal-title":"Frontiers in Pharmacology"},{"key":"10.1016\/j.pharmthera.2022.108300_bb0185","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s12987-015-0017-7","article-title":"Adenosine receptor signaling: A key to opening the blood-brain door","volume":"12","author":"Bynoe","year":"2015","journal-title":"Fluids and Barriers of the CNS"},{"key":"10.1016\/j.pharmthera.2022.108300_bb0195","first-page":"583","article-title":"Engineering a minimal G protein to facilitate crystallisation of G protein-coupled receptors in their active conformation","volume":"29","author":"Carpenter","year":"2016","journal-title":"Protein Engineering, Design & Selection"},{"key":"10.1016\/j.pharmthera.2022.108300_bb0200","doi-asserted-by":"crossref","first-page":"7895","DOI":"10.1073\/pnas.0511232103","article-title":"Inhibition of an equilibrative nucleoside transporter by cannabidiol: a mechanism of cannabinoid immunosuppression","volume":"103","author":"Carrier","year":"2006","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.pharmthera.2022.108300_bb0205","doi-asserted-by":"crossref","first-page":"6844","DOI":"10.3748\/wjg.v27.i40.6844","article-title":"Role of human nucleoside transporters in pancreatic cancer and chemoresistance","volume":"27","author":"Carter","year":"2021","journal-title":"World Journal of Gastroenterology"},{"key":"10.1016\/j.pharmthera.2022.108300_bb0210","first-page":"5879","article-title":"A comparison of the abilities of nitrobenzylthioinosine, dilazep, and dipyridamole to protect human hematopoietic cells from 7-deazaadenosine (tubercidin)","volume":"52","author":"Cass","year":"1992","journal-title":"Cancer Research"},{"key":"10.1016\/j.pharmthera.2022.108300_bb0215","doi-asserted-by":"crossref","first-page":"7250","DOI":"10.1158\/0008-5472.CAN-13-3583","article-title":"Myeloid expression of adenosine A2A receptor suppresses T and NK cell responses in the solid tumor microenvironment","volume":"74","author":"Cekic","year":"2014","journal-title":"Cancer Research"},{"issue":"Pt 2","key":"10.1016\/j.pharmthera.2022.108300_bb0220","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1042\/bj2870461","article-title":"A model for adenosine transport and metabolism","volume":"287","author":"Centelles","year":"1992","journal-title":"The Biochemical Journal"},{"key":"10.1016\/j.pharmthera.2022.108300_bb0225","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1111\/imm.12053","article-title":"Adenosine and cAMP signalling skew human dendritic cell differentiation towards a tolerogenic phenotype with defective CD8(+) T-cell priming capacity","volume":"138","author":"Challier","year":"2013","journal-title":"Immunology"},{"key":"10.1016\/j.pharmthera.2022.108300_bb0230","doi-asserted-by":"crossref","first-page":"60","DOI":"10.3389\/fmolb.2019.00060","article-title":"Immunometabolic dysfunction of natural killer cells mediated by the hypoxia-CD73 axis in solid tumors","volume":"6","author":"Chambers","year":"2019","journal-title":"Frontiers in Molecular Biosciences"},{"key":"10.1016\/j.pharmthera.2022.108300_bb0235","doi-asserted-by":"crossref","first-page":"2533","DOI":"10.3389\/fimmu.2018.02533","article-title":"Adenosinergic signaling alters natural killer cell functional responses","volume":"9","author":"Chambers","year":"2018","journal-title":"Frontiers in Immunology"},{"key":"10.1016\/j.pharmthera.2022.108300_bb0240","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/B978-0-12-801022-8.00012-X","article-title":"Adenosine receptor control of cognition in normal and disease","volume":"119","author":"Chen","year":"2014","journal-title":"International Review of Neurobiology"},{"key":"10.1016\/j.pharmthera.2022.108300_bb0245","doi-asserted-by":"crossref","first-page":"9192","DOI":"10.1523\/JNEUROSCI.19-21-09192.1999","article-title":"A(2A) adenosine receptor deficiency attenuates brain injury induced by transient focal ischemia in mice","volume":"19","author":"Chen","year":"1999","journal-title":"The Journal of Neuroscience"},{"key":"10.1016\/j.pharmthera.2022.108300_bb0250","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/B978-0-12-801022-8.00001-5","article-title":"Adenosine receptor neurobiology: Overview","volume":"119","author":"Chen","year":"2014","journal-title":"International Review of Neurobiology"},{"key":"10.1016\/j.pharmthera.2022.108300_bb0255","first-page":"1668","article-title":"Influence of miR-26b on hepatic cirrhosis and portal pressure in rats with cirrhotic portal hypertension by targeting hENT1 depending on RhoA\/ROCK-1 pathway","volume":"23","author":"Chen","year":"2019","journal-title":"European Review for Medical and Pharmacological Sciences"},{"issue":"1275\u20131285","key":"10.1016\/j.pharmthera.2022.108300_bb0265","first-page":"e1274","article-title":"Structures of Human A1 and A2A Adenosine Receptors with Xanthines Reveal Determinants of Selectivity","volume":"25","author":"Cheng","year":"2017","journal-title":"Structure"},{"key":"10.1016\/j.pharmthera.2022.108300_bb0270","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.entcs.2013.02.016","article-title":"Simulating signalling pathways with BioWayS","volume":"293","author":"Chiarugi","year":"2013","journal-title":"Electronic Notes in Theoretical Computer Science"},{"key":"10.1016\/j.pharmthera.2022.108300_bb0275","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1021\/bc400032x","article-title":"Self-assembling, amphiphilic polymer-gemcitabine conjugate shows enhanced antitumor efficacy against human pancreatic adenocarcinoma","volume":"24","author":"Chitkara","year":"2013","journal-title":"Bioconjugate Chemistry"},{"key":"10.1016\/j.pharmthera.2022.108300_bb0280","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1038\/nn1288","article-title":"The type 1 equilibrative nucleoside transporter regulates ethanol intoxication and preference","volume":"7","author":"Choi","year":"2004","journal-title":"Nature Neuroscience"},{"key":"10.1016\/j.pharmthera.2022.108300_bb0285","doi-asserted-by":"crossref","first-page":"2808","DOI":"10.2174\/1381612825666190712181955","article-title":"Adenosine Receptors in Modulation of Central Nervous System Disorders","volume":"25","author":"Choudhury","year":"2019","journal-title":"Current Pharmaceutical Design"},{"key":"10.1016\/j.pharmthera.2022.108300_bb0290","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.jconrel.2011.08.004","article-title":"Stearoyl gemcitabine nanoparticles overcome resistance related to the over-expression of ribonucleotide reductase subunit M1","volume":"157","author":"Chung","year":"2012","journal-title":"Journal of Controlled Release"},{"key":"10.1016\/j.pharmthera.2022.108300_bb0295","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s11302-008-9100-8","article-title":"Adenosine A(2A) receptors in Parkinson's disease treatment","volume":"4","author":"Cieslak","year":"2008","journal-title":"Purinergic Signal"},{"key":"10.1016\/j.pharmthera.2022.108300_bb0300","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/imm.12117","article-title":"Human dendritic cell subsets","volume":"140","author":"Collin","year":"2013","journal-title":"Immunology"},{"key":"10.1016\/j.pharmthera.2022.108300_bb0305","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1007\/BF00168545","article-title":"Effects of selective A1 and A2 adenosine receptor agonists on cardiovascular tissues","volume":"348","author":"Conti","year":"1993","journal-title":"Naunyn-Schmiedeberg\u2019s Archives of Pharmacology"},{"key":"10.1016\/j.pharmthera.2022.108300_bb0310","first-page":"2535","article-title":"Self-assembled squalenoyl-cytarabine nanostructures as a potent nanomedicine for treatment of leukemic diseases","volume":"7","author":"Cosco","year":"2012","journal-title":"International Journal of Nanomedicine"},{"key":"10.1016\/j.pharmthera.2022.108300_bb0315","doi-asserted-by":"crossref","first-page":"3491","DOI":"10.1096\/fj.08-107458","article-title":"Adenosine A2A receptor activation inhibits T helper 1 and T helper 2 cell development and effector function","volume":"22","author":"Csoka","year":"2008","journal-title":"The FASEB Journal"},{"key":"10.1016\/j.pharmthera.2022.108300_bb0320","doi-asserted-by":"crossref","first-page":"e1178025","DOI":"10.1080\/2162402X.2016.1178025","article-title":"The ecto-ATPDase CD39 is involved in the acquisition of the immunoregulatory phenotype by M-CSF-macrophages and ovarian cancer tumor-associated macrophages: Regulatory role of IL-27","volume":"5","author":"d\u2019Almeida","year":"2016","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.pharmthera.2022.108300_bb0325","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.ijpharm.2014.04.021","article-title":"Preparation, optimization and in vitro characterization of stearoyl-gemcitabine polymeric micelles: A comparison with its self-assembled nanoparticles","volume":"468","author":"Daman","year":"2014","journal-title":"International Journal of Pharmaceutics"},{"key":"10.1016\/j.pharmthera.2022.108300_bb0330","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1158\/1078-0432.CCR-13-2293","article-title":"Erlotinib, gefitinib, and vandetanib inhibit human nucleoside transporters and protect cancer cells from gemcitabine cytotoxicity","volume":"20","author":"Damaraju","year":"2014","journal-title":"Clinical Cancer Research"},{"key":"10.1016\/j.pharmthera.2022.108300_bb0335","doi-asserted-by":"crossref","first-page":"18809","DOI":"10.1074\/jbc.M116.741074","article-title":"Selective inhibition of human equilibrative and concentrative nucleoside transporters by BCR-ABL kinase inhibitors: Identification of key hENT1 amino acid residues for interaction with BCR-ABL kinase inhibitors","volume":"291","author":"Damaraju","year":"2016","journal-title":"The Journal of Biological Chemistry"},{"key":"10.1016\/j.pharmthera.2022.108300_bb0340","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/sj.bjp.0701119","article-title":"Characterization of human A2A adenosine receptors with the antagonist radioligand [3H]-SCH 58261","volume":"121","author":"Dionisotti","year":"1997","journal-title":"British Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2022.108300_bb0345","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1111\/j.1476-5381.1996.tb15561.x","article-title":"Tissue distribution of adenosine receptor mRNAs in the rat","volume":"118","author":"Dixon","year":"1996","journal-title":"British Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2022.108300_bb0350","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.neuint.2014.03.014","article-title":"Nucleoside transporters in the purinome","volume":"73","author":"Dos Santos-Rodrigues","year":"2014","journal-title":"Neurochemistry International"},{"key":"10.1016\/j.pharmthera.2022.108300_bb0355","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1016\/j.phymed.2013.07.009","article-title":"Attenuation of nucleoside and anti-cancer nucleoside analog drug uptake in prostate cancer cells by Cimicifuga racemosa extract BNO-1055","volume":"20","author":"Dueregger","year":"2013","journal-title":"Phytomedicine"},{"key":"10.1016\/j.pharmthera.2022.108300_bb0360","doi-asserted-by":"crossref","first-page":"2710","DOI":"10.1128\/MCB.24.7.2710-2719.2004","article-title":"ATP-sensitive K(+) channels regulate the concentrative adenosine transporter CNT2 following activation by A(1) adenosine receptors","volume":"24","author":"Duflot","year":"2004","journal-title":"Molecular and Cellular Biology"},{"key":"10.1016\/j.pharmthera.2022.108300_bb0365","first-page":"9","article-title":"The role of platelet-derived ADP and ATP in promoting pancreatic cancer cell survival and gemcitabine resistance","author":"Elaskalani","year":"2017","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.pharmthera.2022.108300_bb0370","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1097\/ALN.0b013e3181b060f2","article-title":"Adenosine: An old drug newly discovered","volume":"111","author":"Eltzschig","year":"2009","journal-title":"Anesthesiology"},{"key":"10.1016\/j.pharmthera.2022.108300_bb0375","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s00109-013-0999-z","article-title":"Extracellular adenosine signaling in molecular medicine","volume":"91","author":"Eltzschig","year":"2013","journal-title":"Journal of Molecular Medicine (Berlin, Germany)"},{"key":"10.1016\/j.pharmthera.2022.108300_bb0380","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1084\/jem.20050177","article-title":"HIF-1-dependent repression of equilibrative nucleoside transporter (ENT) in hypoxia","volume":"202","author":"Eltzschig","year":"2005","journal-title":"The Journal of Experimental Medicine"},{"key":"10.1016\/j.pharmthera.2022.108300_bb0385","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1111\/his.12805","article-title":"Low expression of equilibrative nucleoside transporter 1 is associated with poor prognosis in chemotherapy-naive pT2 gallbladder adenocarcinoma patients","volume":"68","author":"Espinoza","year":"2016","journal-title":"Histopathology"},{"key":"10.1016\/j.pharmthera.2022.108300_bb0390","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1002\/ijc.20524","article-title":"Expression of the nucleoside-derived drug transporters hCNT1, hENT1 and hENT2 in gynecologic tumors","volume":"112","author":"Farre","year":"2004","journal-title":"International Journal of Cancer"},{"key":"10.1016\/j.pharmthera.2022.108300_bb0395","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1053\/j.gastro.2008.09.067","article-title":"Human equilibrative nucleoside transporter 1 levels predict response to gemcitabine in patients with pancreatic cancer","volume":"136","author":"Farrell","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.pharmthera.2022.108300_bb0400","doi-asserted-by":"crossref","first-page":"H1671","DOI":"10.1152\/ajpheart.01028.2009","article-title":"Myocardial adenosine A(1)-receptor-mediated adenoprotection involves phospholipase C, PKC-epsilon, and p38 MAPK, but not HSP27","volume":"298","author":"Fenton","year":"2010","journal-title":"American Journal of Physiology. Heart and Circulatory Physiology"},{"key":"10.1016\/j.pharmthera.2022.108300_bb0405","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1016\/S0026-895X(25)10573-7","article-title":"Positive modulation of intracellular Ca2+ levels by adenosine A2b receptors, prostacyclin, and prostaglandin E1 via a cholera toxin-sensitive mechanism in human erythroleukemia cells","volume":"45","author":"Feoktistov","year":"1994","journal-title":"Molecular Pharmacology"},{"key":"10.1016\/j.pharmthera.2022.108300_bb0410","doi-asserted-by":"crossref","first-page":"13589","DOI":"10.1074\/jbc.M109.055673","article-title":"All-trans-retinoic acid promotes trafficking of human concentrative nucleoside transporter-3 (hCNT3) to the plasma membrane by a TGF-beta1-mediated mechanism","volume":"285","author":"Fernandez-Calotti","year":"2010","journal-title":"The Journal of Biological Chemistry"},{"key":"10.1016\/j.pharmthera.2022.108300_bb0415","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1021\/cb5005383","article-title":"Uncovering caffeine\u2019s adenosine A2A receptor inverse agonism in experimental parkinsonism","volume":"9","author":"Fernandez-Duenas","year":"2014","journal-title":"ACS Chemical Biology"},{"key":"10.1016\/j.pharmthera.2022.108300_bb0420","doi-asserted-by":"crossref","first-page":"e1082703","DOI":"10.1080\/2162402X.2015.1082703","article-title":"Phenotypic and functional characteristics of CD39(high) human regulatory B cells (Breg)","volume":"5","author":"Figueiro","year":"2016","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.pharmthera.2022.108300_bb0425","first-page":"2077","article-title":"Targeting the A3 adenosine receptor for cancer therapy: Inhibition of prostate carcinoma cell growth by A3AR agonist","volume":"23","author":"Fishman","year":"2003","journal-title":"Anticancer Research"},{"key":"10.1016\/j.pharmthera.2022.108300_bb0430","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1006\/excr.2001.5327","article-title":"The A3 adenosine receptor as a new target for cancer therapy and chemoprotection","volume":"269","author":"Fishman","year":"2001","journal-title":"Experimental Cell Research"},{"key":"10.1016\/j.pharmthera.2022.108300_bb0435","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1097\/00001813-200206000-00001","article-title":"A3 adenosine receptor as a target for cancer therapy","volume":"13","author":"Fishman","year":"2002","journal-title":"Anti-Cancer Drugs"},{"key":"10.1016\/j.pharmthera.2022.108300_bb0440","doi-asserted-by":"crossref","first-page":"18026","DOI":"10.1074\/jbc.272.29.18026","article-title":"Characterization of a novel Na+\u2212dependent, guanosine-specific, nitrobenzylthioinosine-sensitive transporter in acute promyelocytic leukemia cells","volume":"272","author":"Flanagan","year":"1997","journal-title":"The Journal of Biological Chemistry"},{"key":"10.1016\/j.pharmthera.2022.108300_bb0445","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1111\/j.1365-2982.2008.01213.x","article-title":"A1 and A2a receptors mediate inhibitory effects of adenosine on the motor activity of human colon","volume":"21","author":"Fornai","year":"2009","journal-title":"Neurogastroenterology and Motility"},{"key":"10.1016\/j.pharmthera.2022.108300_bb0450","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.bbrc.2006.02.134","article-title":"Involvement of the concentrative nucleoside transporter 3 and equilibrative nucleoside transporter 2 in the resistance of T-lymphoblastic cell lines to thiopurines","volume":"343","author":"Fotoohi","year":"2006","journal-title":"Biochemical and Biophysical Research Communications"},{"key":"10.1016\/j.pharmthera.2022.108300_bb0455","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1146\/annurev.bi.47.070178.003255","article-title":"The role of adenosine and 2\u2032-deoxyadenosine in mammalian cells","volume":"47","author":"Fox","year":"1978","journal-title":"Annual Review of Biochemistry"},{"key":"10.1016\/j.pharmthera.2022.108300_bb0460","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/S1471-4892(03)00039-0","article-title":"The case for a role for adenosine in asthma: almost convincing?","volume":"3","author":"Fozard","year":"2003","journal-title":"Current Opinion in Pharmacology"},{"key":"10.1016\/j.pharmthera.2022.108300_bb0465","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1038\/sj.cdd.4402132","article-title":"Adenosine, an endogenous distress signal, modulates tissue damage and repair","volume":"14","author":"Fredholm","year":"2007","journal-title":"Cell Death and Differentiation"},{"key":"10.1016\/j.pharmthera.2022.108300_bb0470","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s00109-013-1101-6","article-title":"Adenosine--a physiological or pathophysiological agent?","volume":"92","author":"Fredholm","year":"2014","journal-title":"Journal of Molecular Medicine (Berlin, Germany)"},{"key":"10.1016\/j.pharmthera.2022.108300_bb0475","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1007\/s002100000313","article-title":"Structure and function of adenosine receptors and their genes","volume":"362","author":"Fredholm","year":"2000","journal-title":"Naunyn-Schmiedeberg\u2019s Archives of Pharmacology"},{"key":"10.1016\/j.pharmthera.2022.108300_bb0480","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.pneurobio.2007.07.005","article-title":"Aspects of the general biology of adenosine A2A signaling","volume":"83","author":"Fredholm","year":"2007","journal-title":"Progress in Neurobiology"},{"key":"10.1016\/j.pharmthera.2022.108300_bb0485","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/S0006-2952(00)00570-0","article-title":"Comparison of the potency of adenosine as an agonist at human adenosine receptors expressed in Chinese hamster ovary cells","volume":"61","author":"Fredholm","year":"2001","journal-title":"Biochemical Pharmacology"},{"key":"10.1016\/j.pharmthera.2022.108300_bb0490","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/B978-0-12-385526-8.00003-5","article-title":"Adenosine and the regulation of metabolism and body temperature","volume":"61","author":"Fredholm","year":"2011","journal-title":"Advances in Pharmacology"},{"key":"10.1016\/j.pharmthera.2022.108300_bb0495","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.cell.2017.07.029","article-title":"The PI3K pathway in human disease","volume":"170","author":"Fruman","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.pharmthera.2022.108300_bb0500","first-page":"755","article-title":"MiR-26b regulates invasion and migration of lung cancer cells through targeting hENT1 depending on RhoA\/ROCK-1 pathway","volume":"42","author":"Gao","year":"2017","journal-title":"Zhong Nan Da Xue Xue Bao. Yi Xue Ban"},{"key":"10.1016\/j.pharmthera.2022.108300_bb0505","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.phrs.2008.02.008","article-title":"Translocation of arrestin induced by human A(3) adenosine receptor ligands in an engineered cell line: comparison with G protein-dependent pathways","volume":"57","author":"Gao","year":"2008","journal-title":"Pharmacological Research"},{"key":"10.1016\/j.pharmthera.2022.108300_bb0510","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20205139","article-title":"A2B adenosine receptor and cancer","volume":"20","author":"Gao","year":"2019","journal-title":"International Journal of Molecular Sciences"},{"key":"10.1016\/j.pharmthera.2022.108300_bb0515","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/j.bcp.2011.06.017","article-title":"Functionally biased modulation of A(3) adenosine receptor agonist efficacy and potency by imidazoquinolinamine allosteric enhancers","volume":"82","author":"Gao","year":"2011","journal-title":"Biochemical Pharmacology"},{"key":"10.1016\/j.pharmthera.2022.108300_bb0520","first-page":"5000","article-title":"Nucleoside transporter profiles in human pancreatic cancer cells: Role of hCNT1 in 2\u2032,2\u2032-difluorodeoxycytidine- induced cytotoxicity","volume":"9","author":"Garcia-Manteiga","year":"2003","journal-title":"Clinical Cancer Research"},{"key":"10.1016\/j.pharmthera.2022.108300_bb0525","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1080\/14728222.2017.1323880","article-title":"MUC4 mucin- a therapeutic target for pancreatic ductal adenocarcinoma","volume":"21","author":"Gautam","year":"2017","journal-title":"Expert Opinion on Therapeutic Targets"},{"key":"10.1016\/j.pharmthera.2022.108300_bb0530","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.autneu.2006.03.009","article-title":"Effect of postnatal exposure to caffeine on the pattern of adenosine A1 receptor distribution in respiration-related nuclei of the rat brainstem","volume":"126\u2013127","author":"Gaytan","year":"2006","journal-title":"Autonomic Neuroscience"},{"key":"10.1016\/j.pharmthera.2022.108300_bb0535","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/0165-3806(84)90080-4","article-title":"Ontogenesis of adenosine receptors in the central nervous system of the rat","volume":"315","author":"Geiger","year":"1984","journal-title":"Brain Research"},{"key":"10.1016\/j.pharmthera.2022.108300_bb0540","doi-asserted-by":"crossref","first-page":"229","DOI":"10.2174\/1389450023347713","article-title":"Purine signaling and potential new therapeutic approach: Possible outcomes of NTPDase inhibition","volume":"3","author":"Gendron","year":"2002","journal-title":"Current Drug Targets"},{"key":"10.1016\/j.pharmthera.2022.108300_bb0545","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1517\/13543784.2011.627853","article-title":"Adenosine receptor targeting in health and disease","volume":"20","author":"Gessi","year":"2011","journal-title":"Expert Opinion on Investigational Drugs"},{"key":"10.1016\/j.pharmthera.2022.108300_bb0550","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1016\/j.bbamem.2010.09.020","article-title":"Adenosine receptors and cancer","volume":"1808","author":"Gessi","year":"2011","journal-title":"Biochimica et Biophysica Acta"},{"key":"10.1016\/j.pharmthera.2022.108300_bb0555","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1124\/mol.65.3.711","article-title":"Expression of A3 adenosine receptors in human lymphocytes: up-regulation in T cell activation","volume":"65","author":"Gessi","year":"2004","journal-title":"Molecular Pharmacology"},{"key":"10.1016\/j.pharmthera.2022.108300_bb0560","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1046\/j.1460-9568.2002.02122.x","article-title":"Mice lacking the adenosine A1 receptor are anxious and aggressive, but are normal learners with reduced muscle strength and survival rate","volume":"16","author":"Gimenez-Llort","year":"2002","journal-title":"The European Journal of Neuroscience"},{"key":"10.1016\/j.pharmthera.2022.108300_bb0565","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1159\/000094541","article-title":"Expression of the high-affinity fluoropyrimidine-preferring nucleoside transporter hCNT1 correlates with decreased disease-free survival in breast cancer","volume":"70","author":"Gloeckner-Hofmann","year":"2006","journal-title":"Oncology"},{"issue":"867\u2013877","key":"10.1016\/j.pharmthera.2022.108300_bb0570","first-page":"e813","article-title":"Structure of the adenosine A1 receptor reveals the basis for subtype selectivity","volume":"168","author":"Glukhova","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.pharmthera.2022.108300_bb0575","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1172\/JCI103555","article-title":"Mechanisms of synthesis of purine nucleotides in heart muscle extracts","volume":"36","author":"Goldthwait","year":"1957","journal-title":"The Journal of Clinical Investigation"},{"key":"10.1016\/j.pharmthera.2022.108300_bb0580","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1006\/bbrc.1995.2870","article-title":"Mucin genes are regulated by estrogen and dexamethasone","volume":"217","author":"Gollub","year":"1995","journal-title":"Biochemical and Biophysical Research Communications"},{"key":"10.1016\/j.pharmthera.2022.108300_bb0585","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1021\/jm00036a019","article-title":"Synthesis and structure-activity relationships of deazaxanthines: analogs of potent A1- and A2-adenosine receptor antagonists","volume":"37","author":"Grahner","year":"1994","journal-title":"Journal of Medicinal Chemistry"},{"key":"10.1016\/j.pharmthera.2022.108300_bb0590","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1124\/mol.65.3.512","article-title":"Functional and genetic diversity in the concentrative nucleoside transporter, CNT1, in human populations","volume":"65","author":"Gray","year":"2004","journal-title":"Molecular Pharmacology"},{"key":"10.1016\/j.pharmthera.2022.108300_bb0595","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1111\/j.1471-4159.2004.02545.x","article-title":"Distribution of CNT2 and ENT1 transcripts in rat brain: Selective decrease of CNT2 mRNA in the cerebral cortex of sleep-deprived rats","volume":"90","author":"Guillen-Gomez","year":"2004","journal-title":"Journal of Neurochemistry"},{"key":"10.1016\/j.pharmthera.2022.108300_bb0600","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/j.bmcl.2008.11.112","article-title":"Synthesis and biological evaluation of phloridzin analogs as human concentrative nucleoside transporter 3 (hCNT3) inhibitors","volume":"19","author":"Gupte","year":"2009","journal-title":"Bioorganic & Medicinal Chemistry Letters"},{"key":"10.1016\/j.pharmthera.2022.108300_bb0605","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1593\/neo.10576","article-title":"Interdependence of gemcitabine treatment, transporter expression, and resistance in human pancreatic carcinoma cells","volume":"12","author":"Hagmann","year":"2010","journal-title":"Neoplasia"},{"key":"10.1016\/j.pharmthera.2022.108300_bb0610","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1046\/j.1471-4159.2003.01919.x","article-title":"Evidence for functional adenosine A3 receptors in microglia cells","volume":"86","author":"Hammarberg","year":"2003","journal-title":"Journal of Neurochemistry"},{"key":"10.1016\/j.pharmthera.2022.108300_bb0615","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/s002100000214","article-title":"Interaction of a series of draflazine analogues with equilibrative nucleoside transporters: Species differences and transporter subtype selectivity","volume":"361","author":"Hammond","year":"2000","journal-title":"Naunyn-Schmiedeberg\u2019s Archives of Pharmacology"},{"key":"10.1016\/j.pharmthera.2022.108300_bb0620","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1093\/bioinformatics\/btm560","article-title":"Petri net-based method for the analysis of the dynamics of signal propagation in signaling pathways","volume":"24","author":"Hardy","year":"2008","journal-title":"Bioinformatics"},{"key":"10.1016\/j.pharmthera.2022.108300_bb0625","first-page":"1245","article-title":"A3 adenosine receptor agonist potentiates natural killer cell activity","volume":"23","author":"Harish","year":"2003","journal-title":"International Journal of Oncology"},{"key":"10.1016\/j.pharmthera.2022.108300_bb0630","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.bcp.2018.02.002","article-title":"Adenosine metabolism, immunity and joint health","volume":"151","author":"Hasko","year":"2018","journal-title":"Biochemical Pharmacology"},{"key":"10.1016\/j.pharmthera.2022.108300_bb0635","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.2174\/156802606777812059","article-title":"The purinome, a complex mix of drug and toxicity targets","volume":"6","author":"Haystead","year":"2006","journal-title":"Current Topics in Medicinal Chemistry"},{"key":"10.1016\/j.pharmthera.2022.108300_bb0640","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1093\/carcin\/bgw093","article-title":"TGF-beta-induced stromal CYR61 promotes resistance to gemcitabine in pancreatic ductal adenocarcinoma through downregulation of the nucleoside transporters hENT1 and hCNT3","volume":"37","author":"Hesler","year":"2016","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.pharmthera.2022.108300_bb0645","doi-asserted-by":"crossref","first-page":"10373","DOI":"10.1021\/bi7009647","article-title":"Adenosine deaminase 1 and concentrative nucleoside transporters 2 and 3 regulate adenosine on the apical surface of human airway epithelia: implications for inflammatory lung diseases","volume":"46","author":"Hirsh","year":"2007","journal-title":"Biochemistry"},{"key":"10.1016\/j.pharmthera.2022.108300_bb0650","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1172\/JCI112550","article-title":"Desensitization of adenosine receptor-mediated inhibition of lipolysis. The mechanism involves the development of enhanced cyclic adenosine monophosphate accumulation in tolerant adipocytes","volume":"78","author":"Hoffman","year":"1986","journal-title":"The Journal of Clinical Investigation"},{"key":"10.1016\/j.pharmthera.2022.108300_bb0655","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1182\/blood-2011-02-337840","article-title":"In vitro efficacy of forodesine and nelarabine (ara-G) in pediatric leukemia","volume":"118","author":"Homminga","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2022.108300_bb0660","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1126\/science.1213682","article-title":"Equilibrative nucleoside transporter 3 deficiency perturbs lysosome function and macrophage homeostasis","volume":"335","author":"Hsu","year":"2012","journal-title":"Science"},{"key":"10.1016\/j.pharmthera.2022.108300_bb0665","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.3892\/or.2017.5856","article-title":"FBW7 increases the chemosensitivity of pancreatic cancer cells to gemcitabine through upregulation of ENT1","volume":"38","author":"Hu","year":"2017","journal-title":"Oncology Reports"},{"key":"10.1016\/j.pharmthera.2022.108300_bb0670","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1084\/jem.20061372","article-title":"Enhanced mast cell activation in mice deficient in the A2b adenosine receptor","volume":"204","author":"Hua","year":"2007","journal-title":"The Journal of Experimental Medicine"},{"key":"10.1016\/j.pharmthera.2022.108300_bb0675","doi-asserted-by":"crossref","first-page":"e30468","DOI":"10.1097\/MD.0000000000030468","article-title":"Antiplatelet agents aspirin and dipyridamole, and the risk of different carcinoma in patients with type 2 diabetes mellitus: A Taiwan retrospective cohort study","volume":"101","author":"Huang","year":"2022","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.pharmthera.2022.108300_bb0680","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1081\/NCN-200027667","article-title":"Regulation of equilibrative nucleoside uptake by protein kinase inhibitors","volume":"23","author":"Huang","year":"2004","journal-title":"Nucleosides, Nucleotides & Nucleic Acids"},{"key":"10.1016\/j.pharmthera.2022.108300_bb0685","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1111\/bjh.17851","article-title":"Use of dipyridamole is associated with lower risk of lymphoid neoplasms: A propensity score-matched cohort study","volume":"196","author":"Huang","year":"2022","journal-title":"British Journal of Haematology"},{"key":"10.1016\/j.pharmthera.2022.108300_bb0690","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1007\/s13238-016-0350-x","article-title":"Functional characterization of human equilibrative nucleoside transporter 1","volume":"8","author":"Huang","year":"2017","journal-title":"Protein & Cell"},{"key":"10.1016\/j.pharmthera.2022.108300_bb0695","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.canlet.2015.01.017","article-title":"Defective hCNT1 transport contributes to gemcitabine chemoresistance in ovarian cancer subtypes: Overcoming transport defects using a nanoparticle approach","volume":"359","author":"Hung","year":"2015","journal-title":"Cancer Letters"},{"key":"10.1016\/j.pharmthera.2022.108300_bb0700","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1593\/neo.131748","article-title":"Blockade of A2b adenosine receptor reduces tumor growth and immune suppression mediated by myeloid-derived suppressor cells in a mouse model of melanoma","volume":"15","author":"Iannone","year":"2013","journal-title":"Neoplasia"},{"key":"10.1016\/j.pharmthera.2022.108300_bb0705","doi-asserted-by":"crossref","first-page":"514","DOI":"10.3389\/fimmu.2014.00514","article-title":"From Monocytes to M1\/M2 Macrophages: Phenotypical vs. functional differentiation","volume":"5","author":"Italiani","year":"2014","journal-title":"Frontiers in Immunology"},{"key":"10.1016\/j.pharmthera.2022.108300_bb0710","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1126\/science.1164772","article-title":"The 2.6 angstrom crystal structure of a human A2A adenosine receptor bound to an antagonist","volume":"322","author":"Jaakola","year":"2008","journal-title":"Science"},{"key":"10.1016\/j.pharmthera.2022.108300_bb0715","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s11302-012-9294-7","article-title":"G protein-coupled adenosine (P1) and P2Y receptors: Ligand design and receptor interactions","volume":"8","author":"Jacobson","year":"2012","journal-title":"Purinergic Signal"},{"key":"10.1016\/j.pharmthera.2022.108300_bb0720","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1038\/nrd1983","article-title":"Adenosine receptors as therapeutic targets","volume":"5","author":"Jacobson","year":"2006","journal-title":"Nature Reviews. Drug Discovery"},{"key":"10.1016\/j.pharmthera.2022.108300_bb0725","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1002\/med.21456","article-title":"A3 adenosine receptors as modulators of inflammation: From medicinal chemistry to therapy","volume":"38","author":"Jacobson","year":"2018","journal-title":"Medicinal Research Reviews"},{"key":"10.1016\/j.pharmthera.2022.108300_bb0730","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1593\/neo.09744","article-title":"Adenosine A(3) receptor suppresses prostate cancer metastasis by inhibiting NADPH oxidase activity","volume":"11","author":"Jajoo","year":"2009","journal-title":"Neoplasia"},{"key":"10.1016\/j.pharmthera.2022.108300_bb0735","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1080\/15257770.2020.1746803","article-title":"Expression of the nucleoside transporters hENT1 (SLC29) and hCNT1 (SLC28) in pediatric acute myeloid leukemia","volume":"39","author":"Jaramillo","year":"2020","journal-title":"Nucleosides, Nucleotides & Nucleic Acids"},{"key":"10.1016\/j.pharmthera.2022.108300_bb0740","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1016\/S0028-3908(00)00207-0","article-title":"Distinct regional distribution of human equilibrative nucleoside transporter proteins 1 and 2 (hENT1 and hENT2) in the central nervous system","volume":"40","author":"Jennings","year":"2001","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pharmthera.2022.108300_bb0745","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1007\/s00262-020-02535-6","article-title":"Adenosine-producing regulatory B cells in head and neck cancer","volume":"69","author":"Jeske","year":"2020","journal-title":"Cancer Immunology, Immunotherapy"},{"key":"10.1016\/j.pharmthera.2022.108300_bb0750","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1038\/89661","article-title":"Structural basis for substrate specificities of cellular deoxyribonucleoside kinases","volume":"8","author":"Johansson","year":"2001","journal-title":"Nature Structural Biology"},{"key":"10.1016\/j.pharmthera.2022.108300_bb0755","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1007\/s13318-021-00703-2","article-title":"Differential inhibition of equilibrative nucleoside transporter 1 (ENT1) activity by tyrosine kinase inhibitors","volume":"46","author":"Jouan","year":"2021","journal-title":"European Journal of Drug Metabolism and Pharmacokinetics"},{"key":"10.1016\/j.pharmthera.2022.108300_bb0760","doi-asserted-by":"crossref","first-page":"5904","DOI":"10.4049\/jimmunol.1400336","article-title":"A novel mechanism of B cell-mediated immune suppression through CD73 expression and adenosine production","volume":"193","author":"Kaku","year":"2014","journal-title":"Journal of Immunology"},{"key":"10.1016\/j.pharmthera.2022.108300_bb0765","doi-asserted-by":"crossref","first-page":"28343","DOI":"10.1074\/jbc.M110.109199","article-title":"Human equilibrative nucleoside transporter-3 (hENT3) spectrum disorder mutations impair nucleoside transport, protein localization, and stability","volume":"285","author":"Kang","year":"2010","journal-title":"The Journal of Biological Chemistry"},{"key":"10.1016\/j.pharmthera.2022.108300_bb0770","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1530\/ERC-21-0085","article-title":"Inhibition of GATA2 in prostate cancer by a clinically available small molecule","volume":"29","author":"Kaochar","year":"2021","journal-title":"Endocrine-Related Cancer"},{"key":"10.1016\/j.pharmthera.2022.108300_bb0775","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1165\/rcmb.2013-0089OC","article-title":"Adenosine A2B receptor and hyaluronan modulate pulmonary hypertension associated with chronic obstructive pulmonary disease","volume":"49","author":"Karmouty-Quintana","year":"2013","journal-title":"American Journal of Respiratory Cell and Molecular Biology"},{"key":"10.1016\/j.pharmthera.2022.108300_bb0780","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s00109-013-0997-1","article-title":"Adenosine signaling during acute and chronic disease states","volume":"91","author":"Karmouty-Quintana","year":"2013","journal-title":"Journal of Molecular Medicine (Berlin, Germany)"},{"key":"10.1016\/j.pharmthera.2022.108300_bb0785","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1161\/01.RES.19.2.420","article-title":"Release of adenosine from anoxic hearts: Relationship to coronary flow","volume":"19","author":"Katori","year":"1966","journal-title":"Circulation Research"},{"key":"10.1016\/j.pharmthera.2022.108300_bb0790","first-page":"2739","article-title":"Combined gemcitabine and metronidazole is a promising therapeutic strategy for cancer stem-like cholangiocarcinoma","volume":"38","author":"Kawamoto","year":"2018","journal-title":"Anticancer Research"},{"key":"10.1016\/j.pharmthera.2022.108300_bb0795","doi-asserted-by":"crossref","first-page":"3247","DOI":"10.4049\/jimmunol.1900765","article-title":"Adenosine receptor signaling targets both PKA and Epac pathways to polarize dendritic cells to a suppressive phenotype","volume":"203","author":"Kayhan","year":"2019","journal-title":"Journal of Immunology"},{"key":"10.1016\/j.pharmthera.2022.108300_bb0800","doi-asserted-by":"crossref","first-page":"6649","DOI":"10.1158\/1078-0432.CCR-09-1213","article-title":"Altered tissue 3\u2032-deoxy-3\u2032-[18F]fluorothymidine pharmacokinetics in human breast cancer following capecitabine treatment detected by positron emission tomography","volume":"15","author":"Kenny","year":"2009","journal-title":"Clinical Cancer Research"},{"key":"10.1016\/j.pharmthera.2022.108300_bb0805","first-page":"9","article-title":"Role of NKT cells during viral infection and the development of NKT cell-based nanovaccines","author":"Khan","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.pharmthera.2022.108300_bb0810","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1124\/mol.105.016857","article-title":"Tumor necrosis factor-alpha prevents desensitization of Galphas-coupled receptors by regulating GRK2 association with the plasma membrane","volume":"69","author":"Khoa","year":"2006","journal-title":"Molecular Pharmacology"},{"key":"10.1016\/j.pharmthera.2022.108300_bb0815","doi-asserted-by":"crossref","first-page":"e0209104","DOI":"10.1371\/journal.pone.0209104","article-title":"Human equilibrative nucleoside transporter 1 (hENT1) expression as a predictive biomarker for gemcitabine chemotherapy in biliary tract cancer","volume":"13","author":"Kim","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.pharmthera.2022.108300_bb0820","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1007\/s00280-016-3103-x","article-title":"SLC29A1 (ENT1) polymorphisms and outcome of complete remission in acute myeloid leukemia","volume":"78","author":"Kim","year":"2016","journal-title":"Cancer Chemotherapy and Pharmacology"},{"key":"10.1016\/j.pharmthera.2022.108300_bb0825","doi-asserted-by":"crossref","first-page":"4142","DOI":"10.1021\/jm960482i","article-title":"Derivatives of the triazoloquinazoline adenosine antagonist (CGS15943) are selective for the human A3 receptor subtype","volume":"39","author":"Kim","year":"1996","journal-title":"Journal of Medicinal Chemistry"},{"key":"10.1016\/j.pharmthera.2022.108300_bb0830","first-page":"H820","article-title":"Coupling of ATP-sensitive K+ channels to A1 receptors by G proteins in rat ventricular myocytes","volume":"259","author":"Kirsch","year":"1990","journal-title":"The American Journal of Physiology"},{"key":"10.1016\/j.pharmthera.2022.108300_bb0835","doi-asserted-by":"crossref","first-page":"G936","DOI":"10.1152\/ajpgi.90678.2008","article-title":"Hepatocyte nuclear factor-4alpha and bile acids regulate human concentrative nucleoside transporter-1 gene expression","volume":"296","author":"Klein","year":"2009","journal-title":"American Journal of Physiology. Gastrointestinal and Liver Physiology"},{"key":"10.1016\/j.pharmthera.2022.108300_bb0840","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1007\/s002100000315","article-title":"Adenosine receptors and their ligands","volume":"362","author":"Klotz","year":"2000","journal-title":"Naunyn-Schmiedeberg\u2019s Archives of Pharmacology"},{"key":"10.1016\/j.pharmthera.2022.108300_bb0845","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/PL00005131","article-title":"Comparative pharmacology of human adenosine receptor subtypes - characterization of stably transfected receptors in CHO cells","volume":"357","author":"Klotz","year":"1998","journal-title":"Naunyn-Schmiedeberg\u2019s Archives of Pharmacology"},{"key":"10.1016\/j.pharmthera.2022.108300_bb0850","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1111\/j.1471-4159.1990.tb04902.x","article-title":"Guanine nucleotide effects on 8-cyclopentyl-1,3-[3H]dipropylxanthine binding to membrane-bound and solubilized A1 adenosine receptors of rat brain","volume":"54","author":"Klotz","year":"1990","journal-title":"Journal of Neurochemistry"},{"key":"10.1016\/j.pharmthera.2022.108300_bb0855","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0006784","article-title":"Selective deletion of the A1 adenosine receptor abolishes heart-rate slowing effects of intravascular adenosine in vivo","volume":"4","author":"Koeppen","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/j.pharmthera.2022.108300_bb0860","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1096\/fj.06-6419com","article-title":"HIF-dependent induction of adenosine A2B receptor in hypoxia","volume":"20","author":"Kong","year":"2006","journal-title":"The FASEB Journal"},{"key":"10.1016\/j.pharmthera.2022.108300_bb0865","doi-asserted-by":"crossref","first-page":"63","DOI":"10.2174\/1389200043489162","article-title":"Mammalian nucleoside transporters","volume":"5","author":"Kong","year":"2004","journal-title":"Current Drug Metabolism"},{"key":"10.1016\/j.pharmthera.2022.108300_bb0870","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/S0026-895X(24)12188-8","article-title":"Patterns of A2A extracellular adenosine receptor expression in different functional subsets of human peripheral T cells. Flow cytometry studies with anti-A2A receptor monoclonal antibodies","volume":"55","author":"Koshiba","year":"1999","journal-title":"Molecular Pharmacology"},{"key":"10.1016\/j.pharmthera.2022.108300_bb0875","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.nucmedbio.2016.09.004","article-title":"New potent A1 adenosine receptor radioligands for positron emission tomography","volume":"44","author":"Kreft","year":"2017","journal-title":"Nuclear Medicine and Biology"},{"key":"10.1016\/j.pharmthera.2022.108300_bb0880","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1038\/onc.2014.11","article-title":"miR-219-1-3p is a negative regulator of the mucin MUC4 expression and is a tumor suppressor in pancreatic cancer","volume":"34","author":"Lahdaoui","year":"2015","journal-title":"Oncogene"},{"key":"10.1016\/j.pharmthera.2022.108300_bb0885","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.ijpharm.2012.03.014","article-title":"Synthesis and in vitro evaluation of novel lipophilic monophosphorylated gemcitabine derivatives and their nanoparticles","volume":"429","author":"Lansakara","year":"2012","journal-title":"International Journal of Pharmaceutics"},{"key":"10.1016\/j.pharmthera.2022.108300_bb0890","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1046\/j.1471-4159.2001.00607.x","article-title":"Adenosine in the central nervous system: release mechanisms and extracellular concentrations","volume":"79","author":"Latini","year":"2001","journal-title":"Journal of Neurochemistry"},{"key":"10.1016\/j.pharmthera.2022.108300_bb0895","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s11302-012-9304-9","article-title":"Vesicular and conductive mechanisms of nucleotide release","volume":"8","author":"Lazarowski","year":"2012","journal-title":"Purinergic Signal"},{"key":"10.1016\/j.pharmthera.2022.108300_bb0900","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.jmb.2011.03.075","article-title":"Thermostabilisation of an agonist-bound conformation of the human adenosine A(2A) receptor","volume":"409","author":"Lebon","year":"2011","journal-title":"Journal of Molecular Biology"},{"key":"10.1016\/j.pharmthera.2022.108300_bb0905","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1051\/medsci\/20112711004","article-title":"Structure of the adenosine-bound conformation of the human adenosine A(2A) receptor","volume":"27","author":"Lebon","year":"2011","journal-title":"Medical Science (Paris)"},{"key":"10.1016\/j.pharmthera.2022.108300_bb0910","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/nature10136","article-title":"Agonist-bound adenosine A2A receptor structures reveal common features of GPCR activation","volume":"474","author":"Lebon","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2022.108300_bb0915","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1038\/41771","article-title":"Aggressiveness, hypoalgesia and high blood pressure in mice lacking the adenosine A2a receptor","volume":"388","author":"Ledent","year":"1997","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2022.108300_bb0920","doi-asserted-by":"crossref","first-page":"763","DOI":"10.3892\/or.2012.2172","article-title":"Etoposide increases equilibrative nucleoside transporter 1 activity and fluorothymidine uptake: screening of 60 cytotoxic agents","volume":"29","author":"Lee","year":"2013","journal-title":"Oncology Reports"},{"key":"10.1016\/j.pharmthera.2022.108300_bb0925","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1046\/j.1460-9568.2003.02907.x","article-title":"Characterization of the rat A2A adenosine receptor gene: a 4.8-kb promoter-proximal DNA fragment confers selective expression in the central nervous system","volume":"18","author":"Lee","year":"2003","journal-title":"The European Journal of Neuroscience"},{"key":"10.1016\/j.pharmthera.2022.108300_bb0930","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.bbrc.2010.11.125","article-title":"Regulation of ENT1 expression and ENT1-dependent nucleoside transport by c-Jun N-terminal kinase","volume":"404","author":"Leisewitz","year":"2011","journal-title":"Biochemical and Biophysical Research Communications"},{"key":"10.1016\/j.pharmthera.2022.108300_bb0935","doi-asserted-by":"crossref","first-page":"3623","DOI":"10.1021\/jm4011669","article-title":"Adenosine A2A receptor as a drug discovery target","volume":"57","author":"de Lera Ruiz","year":"2014","journal-title":"Journal of Medicinal Chemistry"},{"key":"10.1016\/j.pharmthera.2022.108300_bb0940","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.bcp.2005.05.010","article-title":"Effect of thiazolidinediones on equilibrative nucleoside transporter-1 in human aortic smooth muscle cells","volume":"70","author":"Leung","year":"2005","journal-title":"Biochemical Pharmacology"},{"key":"10.1016\/j.pharmthera.2022.108300_bb0945","doi-asserted-by":"crossref","first-page":"3186","DOI":"10.1021\/jm980093j","article-title":"Structure-activity relationships and molecular modeling of 3, 5-diacyl-2,4-dialkylpyridine derivatives as selective A3 adenosine receptor antagonists","volume":"41","author":"Li","year":"1998","journal-title":"Journal of Medicinal Chemistry"},{"key":"10.1016\/j.pharmthera.2022.108300_bb0950","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.dci.2016.01.010","article-title":"The M2 macrophages induce autophagic vascular disorder and promote mouse sensitivity to urethane-related lung carcinogenesis","volume":"59","author":"Li","year":"2016","journal-title":"Developmental and Comparative Immunology"},{"key":"10.1016\/j.pharmthera.2022.108300_bb0955","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1186\/1556-276X-8-176","article-title":"Gemcitabine-loaded albumin nanospheres (GEM-ANPs) inhibit PANC-1 cells in vitro and in vivo","volume":"8","author":"Li","year":"2013","journal-title":"Nanoscale Research Letters"},{"key":"10.1016\/j.pharmthera.2022.108300_bb0960","doi-asserted-by":"crossref","first-page":"837555","DOI":"10.3389\/fphar.2022.837555","article-title":"Structure-activity relationship studies of 4-((4-(2-fluorophenyl)piperazin-1-yl)methyl)-6-imino-N-(naphthalen-2-yl)-1,3,5-tr iazin-2-amine (FPMINT) analogues as inhibitors of human equilibrative nucleoside transporters","volume":"13","author":"Li","year":"2022","journal-title":"Frontiers in Pharmacology"},{"key":"10.1016\/j.pharmthera.2022.108300_bb0965","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1161\/ATVBAHA.111.226837","article-title":"Regulation of lymphocyte function by adenosine","volume":"32","author":"Linden","year":"2012","journal-title":"Arteriosclerosis, Thrombosis, and Vascular Biology"},{"key":"10.1016\/j.pharmthera.2022.108300_bb0970","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/S0026-895X(24)12531-X","article-title":"Characterization of human A(2B) adenosine receptors: radioligand binding, western blotting, and coupling to G(q) in human embryonic kidney 293 cells and HMC-1 mast cells","volume":"56","author":"Linden","year":"1999","journal-title":"Molecular Pharmacology"},{"issue":"679\u2013692","key":"10.1016\/j.pharmthera.2022.108300_bb0975","first-page":"e671","article-title":"ZIP4 increases expression of transcription factor ZEB1 to promote integrin alpha3beta1 signaling and inhibit expression of the gemcitabine transporter ENT1 in pancreatic cancer cells","volume":"158","author":"Liu","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.pharmthera.2022.108300_bb0980","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1097\/00005344-200009000-00011","article-title":"Inhibition of adenosine uptake and augmentation of ischemia-induced increase of interstitial adenosine by cilostazol, an agent to treat intermittent claudication","volume":"36","author":"Liu","year":"2000","journal-title":"Journal of Cardiovascular Pharmacology"},{"key":"10.1016\/j.pharmthera.2022.108300_bb0985","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1111\/cns.13190","article-title":"Research progress on adenosine in central nervous system diseases","volume":"25","author":"Liu","year":"2019","journal-title":"CNS Neuroscience & Therapeutics"},{"key":"10.1016\/j.pharmthera.2022.108300_bb0990","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s00011-004-1248-2","article-title":"Adenosine, inflammation and asthma--a review","volume":"53","author":"Livingston","year":"2004","journal-title":"Inflammation Research"},{"key":"10.1016\/j.pharmthera.2022.108300_bb0995","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1161\/ATVBAHA.106.126714","article-title":"Physiological roles of vascular nucleoside transporters","volume":"27","author":"Loffler","year":"2007","journal-title":"Arteriosclerosis, Thrombosis, and Vascular Biology"},{"key":"10.1016\/j.pharmthera.2022.108300_bb1000","doi-asserted-by":"crossref","first-page":"7758","DOI":"10.1158\/0008-5472.CAN-06-0478","article-title":"Adenosine-mediated inhibition of the cytotoxic activity and cytokine production by activated natural killer cells","volume":"66","author":"Lokshin","year":"2006","journal-title":"Cancer Research"},{"key":"10.1016\/j.pharmthera.2022.108300_bb1005","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1124\/dmd.104.001123","article-title":"Tissue distribution of concentrative and equilibrative nucleoside transporters in male and female rats and mice","volume":"32","author":"Lu","year":"2004","journal-title":"Drug Metabolism and Disposition"},{"key":"10.1016\/j.pharmthera.2022.108300_bb1010","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1046\/j.1359-4117.2002.01035.x","article-title":"Correlation of nucleoside and nucleobase transporter gene expression with antimetabolite drug cytotoxicity","volume":"2","author":"Lu","year":"2002","journal-title":"Journal of Experimental Therapeutics & Oncology"},{"key":"10.1016\/j.pharmthera.2022.108300_bb1015","doi-asserted-by":"crossref","first-page":"e37203","DOI":"10.1371\/journal.pone.0037203","article-title":"Bone marrow stromal cells modulate mouse ENT1 activity and protect leukemia cells from cytarabine induced apoptosis","volume":"7","author":"Macanas-Pirard","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.pharmthera.2022.108300_bb1020","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.canlet.2013.07.037","article-title":"Guggulsterone decreases proliferation and metastatic behavior of pancreatic cancer cells by modulating JAK\/STAT and Src\/FAK signaling","volume":"341","author":"Macha","year":"2013","journal-title":"Cancer Letters"},{"key":"10.1016\/j.pharmthera.2022.108300_bb1025","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.ijpharm.2014.11.009","article-title":"Gemcitabine-based therapy for pancreatic cancer using the squalenoyl nucleoside monophosphate nanoassemblies","volume":"482","author":"Maksimenko","year":"2015","journal-title":"International Journal of Pharmaceutics"},{"key":"10.1016\/j.pharmthera.2022.108300_bb1030","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1007\/s13402-020-00548-y","article-title":"Co-expression analysis of pancreatic cancer proteome reveals biology and prognostic biomarkers","volume":"43","author":"Mantini","year":"2020","journal-title":"Cellular Oncology (Dordrecht)"},{"key":"10.1016\/j.pharmthera.2022.108300_bb1035","doi-asserted-by":"crossref","first-page":"170","DOI":"10.7861\/clinmedicine.7-2-170","article-title":"Drug-induced disorders of the nervous system","volume":"7","author":"Mark","year":"2007","journal-title":"Clinical Medicine (London, England)"},{"key":"10.1016\/j.pharmthera.2022.108300_bb1040","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/S0022-3565(25)38124-3","article-title":"2-Phenylethoxy-9-methyladenine: An adenosine receptor antagonist that discriminates between A2 adenosine receptors in the aorta and the coronary vessels from the guinea pig","volume":"265","author":"Martin","year":"1993","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/j.pharmthera.2022.108300_bb1045","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/S0022-3565(25)12299-4","article-title":"Characterization of 8-(N-methylisopropyl)amino-N6-(5\u2032-endohydroxy- endonorbornyl)-9-methyladenine (WRC-0571), a highly potent and selective, non-xanthine antagonist of A1 adenosine receptors","volume":"276","author":"Martin","year":"1996","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/j.pharmthera.2022.108300_bb1050","doi-asserted-by":"crossref","first-page":"3723","DOI":"10.4161\/cc.8.22.10026","article-title":"Chemotherapy induces ATP release from tumor cells","volume":"8","author":"Martins","year":"2009","journal-title":"Cell Cycle"},{"key":"10.1016\/j.pharmthera.2022.108300_bb1055","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1186\/s40425-019-0719-5","article-title":"Adenosine mediates functional and metabolic suppression of peripheral and tumor-infiltrating CD8(+) T cells","volume":"7","author":"Mastelic-Gavillet","year":"2019","journal-title":"Journal for Immunotherapy of Cancer"},{"key":"10.1016\/j.pharmthera.2022.108300_bb1060","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/s41388-021-02090-z","article-title":"Cancer biology and molecular genetics of A3 adenosine receptor","volume":"41","author":"Mazziotta","year":"2022","journal-title":"Oncogene"},{"key":"10.1016\/j.pharmthera.2022.108300_bb1065","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1007\/s00262-019-02430-9","article-title":"Histone deacetylase inhibition promotes intratumoral CD8(+) T-cell responses, sensitizing murine breast tumors to anti-PD1","volume":"68","author":"McCaw","year":"2019","journal-title":"Cancer Immunology, Immunotherapy"},{"key":"10.1016\/j.pharmthera.2022.108300_bb1070","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1126\/science.1084238","article-title":"Recruitment of HIV and its receptors to dendritic cell-T cell junctions","volume":"300","author":"McDonald","year":"2003","journal-title":"Science"},{"key":"10.1016\/j.pharmthera.2022.108300_bb1075","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1046\/j.1471-4159.1994.62030992.x","article-title":"Characterization and localization of adenosine A2 receptors in bovine rod outer segments","volume":"62","author":"McIntosh","year":"1994","journal-title":"Journal of Neurochemistry"},{"key":"10.1016\/j.pharmthera.2022.108300_bb1080","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1002\/jcp.1041550311","article-title":"CSF-1 stimulates nucleoside transport in S1 macrophages","volume":"155","author":"Meckling-Gill","year":"1993","journal-title":"Journal of Cellular Physiology"},{"key":"10.1016\/j.pharmthera.2022.108300_bb1085","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1042\/BJ20130231","article-title":"Hypoxia and P1 receptor activation regulate the high-affinity concentrative adenosine transporter CNT2 in differentiated neuronal PC12 cells","volume":"454","author":"Medina-Pulido","year":"2013","journal-title":"The Biochemical Journal"},{"key":"10.1016\/j.pharmthera.2022.108300_bb1090","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.expneurol.2011.09.036","article-title":"Ecto-ATPase inhibition: ATP and adenosine release under physiological and ischemic in vivo conditions in the rat striatum","volume":"233","author":"Melani","year":"2012","journal-title":"Experimental Neurology"},{"key":"10.1016\/j.pharmthera.2022.108300_bb1095","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.1021\/acsnano.5b00510","article-title":"Use of a lipid-coated mesoporous silica nanoparticle platform for synergistic gemcitabine and paclitaxel delivery to human pancreatic cancer in mice","volume":"9","author":"Meng","year":"2015","journal-title":"ACS Nano"},{"key":"10.1016\/j.pharmthera.2022.108300_bb1100","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1124\/dmd.120.090720","article-title":"Nucleoside reverse transcriptase inhibitor interaction with human equilibrative nucleoside transporters 1 and 2","volume":"48","author":"Miller","year":"2020","journal-title":"Drug Metabolism and Disposition"},{"key":"10.1016\/j.pharmthera.2022.108300_bb1105","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1124\/dmd.121.000423","article-title":"Multiple computational approaches for predicting drug interactions with human equilibrative nucleoside transporter 1","volume":"49","author":"Miller","year":"2021","journal-title":"Drug Metabolism and Disposition"},{"key":"10.1016\/j.pharmthera.2022.108300_bb1110","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1124\/jpet.107.131482","article-title":"Expression and functionality of anti-human immunodeficiency virus and anticancer drug uptake transporters in immune cells","volume":"324","author":"Minuesa","year":"2008","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"issue":"Pt 4","key":"10.1016\/j.pharmthera.2022.108300_bb1115","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1242\/jcs.112.4.491","article-title":"Expression of A2B adenosine receptors in human lymphocytes: Their role in T cell activation","volume":"112","author":"Mirabet","year":"1999","journal-title":"Journal of Cell Science"},{"key":"10.1016\/j.pharmthera.2022.108300_bb1120","doi-asserted-by":"crossref","first-page":"57","DOI":"10.4103\/1735-5362.220968","article-title":"Estrogen stimulates adenosine receptor expression subtypes in human breast cancer MCF-7 cell line","volume":"13","author":"Mohamadi","year":"2018","journal-title":"Research in Pharmaceutical Sciences"},{"key":"10.1016\/j.pharmthera.2022.108300_bb1125","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1182\/blood-2002-07-2236","article-title":"Fludarabine uptake mechanisms in B-cell chronic lymphocytic leukemia","volume":"101","author":"Molina-Arcas","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2022.108300_bb1130","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s40425-016-0154-9","article-title":"Adenosine-generating ovarian cancer cells attract myeloid cells which differentiate into adenosine-generating tumor associated macrophages - a self-amplifying, CD39- and CD73-dependent mechanism for tumor immune escape","volume":"4","author":"Montalban Del Barrio","year":"2016","journal-title":"Journal for Immunotherapy of Cancer"},{"key":"10.1016\/j.pharmthera.2022.108300_bb1135","first-page":"1201","article-title":"Human equilibrative nucleoside transporter 1 is associated with the chemosensitivity of gemcitabine in human pancreatic adenocarcinoma and biliary tract carcinoma cells","volume":"17","author":"Mori","year":"2007","journal-title":"Oncology Reports"},{"key":"10.1016\/j.pharmthera.2022.108300_bb1140","doi-asserted-by":"crossref","first-page":"3987","DOI":"10.1021\/jm980036q","article-title":"A novel class of adenosine A3 receptor ligands. 1. 3-(2-Pyridinyl)isoquinoline derivatives","volume":"41","author":"van Muijlwijk-Koezen","year":"1998","journal-title":"Journal of Medicinal Chemistry"},{"key":"10.1016\/j.pharmthera.2022.108300_bb1145","doi-asserted-by":"crossref","first-page":"3994","DOI":"10.1021\/jm980037i","article-title":"A novel class of adenosine A3 receptor ligands. 2. Structure affinity profile of a series of isoquinoline and quinazoline compounds","volume":"41","author":"van Muijlwijk-Koezen","year":"1998","journal-title":"Journal of Medicinal Chemistry"},{"key":"10.1016\/j.pharmthera.2022.108300_bb1150","first-page":"707","article-title":"8-(Sulfostyryl)xanthines: Water-soluble A2A-selective adenosine receptor antagonists","volume":"6","author":"Muller","year":"1998","journal-title":"Bioorganic & Medicinal Chemistry"},{"key":"10.1016\/j.pharmthera.2022.108300_bb1155","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1002\/ijc.23956","article-title":"Polymorphisms in ABCG2, ABCC3 and CNT1 genes and their possible impact on chemotherapy outcome of lung cancer patients","volume":"124","author":"Muller","year":"2009","journal-title":"International Journal of Cancer"},{"key":"10.1016\/j.pharmthera.2022.108300_bb1160","doi-asserted-by":"crossref","first-page":"8723","DOI":"10.1021\/bi990361v","article-title":"Characterization of G protein-coupled receptor regulation in antisense mRNA-expressing cells with reduced arrestin levels","volume":"38","author":"Mundell","year":"1999","journal-title":"Biochemistry"},{"key":"10.1016\/j.pharmthera.2022.108300_bb1165","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1124\/mol.61.2.455","article-title":"Human A(2A) adenosine receptors: High-affinity agonist binding to receptor-G protein complexes containing Gbeta(4)","volume":"61","author":"Murphree","year":"2002","journal-title":"Molecular Pharmacology"},{"key":"10.1016\/j.pharmthera.2022.108300_bb1170","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.immuni.2014.06.008","article-title":"Macrophage activation and polarization: Nomenclature and experimental guidelines","volume":"41","author":"Murray","year":"2014","journal-title":"Immunity"},{"key":"10.1016\/j.pharmthera.2022.108300_bb1175","doi-asserted-by":"crossref","first-page":"5197626","DOI":"10.1155\/2020\/5197626","article-title":"Equilibrative nucleoside transporter 2: Properties and physiological roles","volume":"2020","author":"Naes","year":"2020","journal-title":"BioMed Research International"},{"key":"10.1016\/j.pharmthera.2022.108300_bb1180","doi-asserted-by":"crossref","first-page":"2943","DOI":"10.1038\/s41467-019-10925-3","article-title":"Adult stem cell deficits drive Slc29a3 disorders in mice","volume":"10","author":"Nair","year":"2019","journal-title":"Nature Communications"},{"key":"10.1016\/j.pharmthera.2022.108300_bb1185","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1042\/bj0740127","article-title":"The incorportion of 15Ninto adenine nucleotides and their formation from inosine monophosphate by skeletal-muscle preparations","volume":"74","author":"Newton","year":"1960","journal-title":"The Biochemical Journal"},{"key":"10.1016\/j.pharmthera.2022.108300_bb1190","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.189","article-title":"Clearance of rapid adenosine release is regulated by nucleoside transporters and metabolism","volume":"3","author":"Nguyen","year":"2015","journal-title":"Pharmacology Research & Perspectives"},{"key":"10.1016\/j.pharmthera.2022.108300_bb1195","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.cell.2016.06.028","article-title":"Emt: 2016","volume":"166","author":"Nieto","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.pharmthera.2022.108300_bb1200","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1111\/j.1349-7006.2010.01837.x","article-title":"Disrupted plasma membrane localization of equilibrative nucleoside transporter 2 in the chemoresistance of human pancreatic cells to gemcitabine (dFdCyd)","volume":"102","author":"Nishio","year":"2011","journal-title":"Cancer Science"},{"key":"10.1016\/j.pharmthera.2022.108300_bb1205","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejphar.2004.05.003","article-title":"Adenosine uptake inhibitors","volume":"495","author":"Noji","year":"2004","journal-title":"European Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2022.108300_bb1210","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/0922-4106(94)90159-7","article-title":"KF17837 ((E)-8-(3,4-dimethoxystyryl)-1,3-dipropyl-7-methylxanthine), a potent and selective adenosine A2 receptor antagonist","volume":"267","author":"Nonaka","year":"1994","journal-title":"European Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2022.108300_bb1215","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/S0026-895X(25)09820-7","article-title":"Binding of [3H]KF17837S, a selective adenosine A2 receptor antagonist, to rat brain membranes","volume":"46","author":"Nonaka","year":"1994","journal-title":"Molecular Pharmacology"},{"key":"10.1016\/j.pharmthera.2022.108300_bb1220","doi-asserted-by":"crossref","first-page":"109","DOI":"10.3389\/fimmu.2016.00109","article-title":"A Metabolic immune checkpoint: Adenosine in tumor microenvironment","volume":"7","author":"Ohta","year":"2016","journal-title":"Frontiers in Immunology"},{"key":"10.1016\/j.pharmthera.2022.108300_bb1225","doi-asserted-by":"crossref","first-page":"5487","DOI":"10.4049\/jimmunol.0901247","article-title":"A2A adenosine receptor may allow expansion of T cells lacking effector functions in extracellular adenosine-rich microenvironments","volume":"183","author":"Ohta","year":"2009","journal-title":"Journal of Immunology"},{"key":"10.1016\/j.pharmthera.2022.108300_bb1230","doi-asserted-by":"crossref","first-page":"304","DOI":"10.3389\/fimmu.2014.00304","article-title":"Extracellular adenosine-mediated modulation of regulatory T cells","volume":"5","author":"Ohta","year":"2014","journal-title":"Frontiers in Immunology"},{"key":"10.1016\/j.pharmthera.2022.108300_bb1235","first-page":"F404","article-title":"Selective A2A adenosine receptor activation reduces ischemia-reperfusion injury in rat kidney","volume":"277","author":"Okusa","year":"1999","journal-title":"The American Journal of Physiology"},{"key":"10.1016\/j.pharmthera.2022.108300_bb1240","doi-asserted-by":"crossref","first-page":"18016","DOI":"10.1016\/S0021-9258(17)32411-0","article-title":"Identification of an adenosine receptor domain specifically involved in binding of 5\u2032-substituted adenosine agonists","volume":"269","author":"Olah","year":"1994","journal-title":"The Journal of Biological Chemistry"},{"key":"10.1016\/j.pharmthera.2022.108300_bb1245","doi-asserted-by":"crossref","first-page":"2356","DOI":"10.1002\/pro.246","article-title":"Progress toward heterologous expression of active G-protein-coupled receptors in Saccharomyces cerevisiae: Linking cellular stress response with translocation and trafficking","volume":"18","author":"O\u2019Malley","year":"2009","journal-title":"Protein Science"},{"key":"10.1016\/j.pharmthera.2022.108300_bb1250","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.neuint.2004.12.005","article-title":"Activation of glutamate receptors promotes a calcium-dependent and transporter-mediated release of purines in cultured avian retinal cells: possible involvement of calcium\/calmodulin-dependent protein kinase II","volume":"46","author":"Paes-de-Carvalho","year":"2005","journal-title":"Neurochemistry International"},{"key":"10.1016\/j.pharmthera.2022.108300_bb1255","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1016\/S0026-895X(25)10585-3","article-title":"125I-4-(2-[7-amino-2-[2-furyl][1,2,4]triazolo[2,3-a][1,3,5] triazin-5-yl-amino]ethyl)phenol, a high affinity antagonist radioligand selective for the A2a adenosine receptor","volume":"48","author":"Palmer","year":"1995","journal-title":"Molecular Pharmacology"},{"key":"10.1016\/j.pharmthera.2022.108300_bb1260","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1177\/030089161209800119","article-title":"Expression of A1 and A3 adenosine receptors in human breast tumors","volume":"98","author":"Panjehpour","year":"2012","journal-title":"Tumori"},{"key":"10.1016\/j.pharmthera.2022.108300_bb1265","doi-asserted-by":"crossref","first-page":"3985","DOI":"10.1182\/blood-2002-07-2113","article-title":"Adenosine affects expression of membrane molecules, cytokine and chemokine release, and the T-cell stimulatory capacity of human dendritic cells","volume":"101","author":"Panther","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2022.108300_bb1270","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1096\/fj.01-0169com","article-title":"Expression and function of adenosine receptors in human dendritic cells","volume":"15","author":"Panther","year":"2001","journal-title":"The FASEB Journal"},{"key":"10.1016\/j.pharmthera.2022.108300_bb1275","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1186\/1471-2407-12-419","article-title":"Mechanistic studies of Gemcitabine-loaded nanoplatforms in resistant pancreatic cancer cells","volume":"12","author":"Papa","year":"2012","journal-title":"BMC Cancer"},{"key":"10.1016\/j.pharmthera.2022.108300_bb1280","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/s13402-013-0146-4","article-title":"PEGylated liposomal gemcitabine: Insights into a potential breast cancer therapeutic","volume":"36","author":"Papa","year":"2013","journal-title":"Cellular Oncology (Dordrecht)"},{"key":"10.1016\/j.pharmthera.2022.108300_bb1285","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0056423","article-title":"Human concentrative nucleoside transporter 3 transfection with ultrasound and microbubbles in nucleoside transport deficient HEK293 cells greatly increases gemcitabine uptake","volume":"8","author":"Paproski","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.pharmthera.2022.108300_bb1290","doi-asserted-by":"crossref","first-page":"948","DOI":"10.2174\/156802611795347582","article-title":"Molecular biology of nucleoside transporters and their distributions and functions in the brain","volume":"11","author":"Parkinson","year":"2011","journal-title":"Current Topics in Medicinal Chemistry"},{"key":"10.1016\/j.pharmthera.2022.108300_bb1295","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/0006-2952(93)90499-M","article-title":"Inhibitory effects of propentofylline on [3H]adenosine influx. A study of three nucleoside transport systems","volume":"46","author":"Parkinson","year":"1993","journal-title":"Biochemical Pharmacology"},{"key":"10.1016\/j.pharmthera.2022.108300_bb1300","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/0306-3623(94)90119-8","article-title":"Propentofylline: A nucleoside transport inhibitor with neuroprotective effects in cerebral ischemia","volume":"25","author":"Parkinson","year":"1994","journal-title":"General Pharmacology"},{"key":"10.1016\/j.pharmthera.2022.108300_bb1305","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23031219","article-title":"Adenosine receptors in neuropsychiatric disorders: Fine regulators of neurotransmission and potential therapeutic targets","volume":"23","author":"Pasquini","year":"2022","journal-title":"International Journal of Molecular Sciences"},{"key":"10.1016\/j.pharmthera.2022.108300_bb1310","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1080\/096876800110033783","article-title":"Complex regulation of nucleoside transporter expression in epithelial and immune system cells","volume":"18","author":"Pastor-Anglada","year":"2001","journal-title":"Molecular Membrane Biology"},{"key":"10.1016\/j.pharmthera.2022.108300_bb1315","doi-asserted-by":"crossref","first-page":"13","DOI":"10.3389\/fphar.2015.00013","article-title":"Nucleoside transporter proteins as biomarkers of drug responsiveness and drug targets","volume":"6","author":"Pastor-Anglada","year":"2015","journal-title":"Frontiers in Pharmacology"},{"key":"10.1016\/j.pharmthera.2022.108300_bb1320","doi-asserted-by":"crossref","first-page":"606","DOI":"10.3389\/fphar.2018.00606","article-title":"Emerging roles of nucleoside transporters","volume":"9","author":"Pastor-Anglada","year":"2018","journal-title":"Frontiers in Pharmacology"},{"key":"10.1016\/j.pharmthera.2022.108300_bb1325","doi-asserted-by":"crossref","first-page":"627","DOI":"10.3389\/fphar.2018.00627","article-title":"Who is who in adenosine transport","volume":"9","author":"Pastor-Anglada","year":"2018","journal-title":"Frontiers in Pharmacology"},{"key":"10.1016\/j.pharmthera.2022.108300_bb1330","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.coi.2019.02.003","article-title":"Dendritic cells are what they eat: How their metabolism shapes T helper cell polarization","volume":"58","author":"Patente","year":"2019","journal-title":"Current Opinion in Immunology"},{"key":"10.1016\/j.pharmthera.2022.108300_bb1335","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1006\/bbrc.2000.4205","article-title":"Differential expression of human nucleoside transporters in normal and tumor tissue","volume":"280","author":"Pennycooke","year":"2001","journal-title":"Biochemical and Biophysical Research Communications"},{"key":"10.1016\/j.pharmthera.2022.108300_bb1340","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.bcp.2008.05.011","article-title":"Adenoviral-mediated overexpression of human equilibrative nucleoside transporter 1 (hENT1) enhances gemcitabine response in human pancreatic cancer","volume":"76","author":"Perez-Torras","year":"2008","journal-title":"Biochemical Pharmacology"},{"key":"10.1016\/j.pharmthera.2022.108300_bb1345","doi-asserted-by":"crossref","first-page":"e648","DOI":"10.1038\/cddis.2013.173","article-title":"Concentrative nucleoside transporter 1 (hCNT1) promotes phenotypic changes relevant to tumor biology in a translocation-independent manner","volume":"4","author":"Perez-Torras","year":"2013","journal-title":"Cell Death & Disease"},{"key":"10.1016\/j.pharmthera.2022.108300_bb1350","first-page":"7404","article-title":"Enhancing the potency of chemotherapeutic agents by combination with bromelain and N-acetylcysteine - an in vitro study with pancreatic and hepatic cancer cells","volume":"12","author":"Pillai","year":"2020","journal-title":"American Journal of Translational Research"},{"key":"10.1016\/j.pharmthera.2022.108300_bb1355","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1111\/j.1471-4159.2005.03071.x","article-title":"Adenosine A2A receptors control the extracellular levels of adenosine through modulation of nucleoside transporters activity in the rat hippocampus","volume":"93","author":"Pinto-Duarte","year":"2005","journal-title":"Journal of Neurochemistry"},{"key":"10.1016\/j.pharmthera.2022.108300_bb1360","doi-asserted-by":"crossref","first-page":"5801","DOI":"10.1016\/j.bmcl.2014.10.026","article-title":"Dilazep analogues for the study of equilibrative nucleoside transporters 1 and 2 (ENT1 and ENT2)","volume":"24","author":"Playa","year":"2014","journal-title":"Bioorganic & Medicinal Chemistry Letters"},{"key":"10.1016\/j.pharmthera.2022.108300_bb1365","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/nrd4051","article-title":"Validating therapeutic targets through human genetics","volume":"12","author":"Plenge","year":"2013","journal-title":"Nature Reviews. Drug Discovery"},{"key":"10.1016\/j.pharmthera.2022.108300_bb1370","doi-asserted-by":"crossref","first-page":"699","DOI":"10.2174\/138945006777435236","article-title":"Adenosine receptors as promising therapeutic targets for drug development in chronic airway inflammation","volume":"7","author":"Polosa","year":"2006","journal-title":"Current Drug Targets"},{"key":"10.1016\/j.pharmthera.2022.108300_bb1375","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S0968-0896(98)00038-8","article-title":"Adenosine receptors: New opportunities for future drugs","volume":"6","author":"Poulsen","year":"1998","journal-title":"Bioorganic & Medicinal Chemistry"},{"key":"10.1016\/j.pharmthera.2022.108300_bb1380","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1002\/med.21344","article-title":"History and perspectives of A2A adenosine receptor antagonists as potential therapeutic agents","volume":"35","author":"Preti","year":"2015","journal-title":"Medicinal Research Reviews"},{"key":"10.1016\/j.pharmthera.2022.108300_bb1385","doi-asserted-by":"crossref","first-page":"14775","DOI":"10.1074\/jbc.M117.787952","article-title":"Molecular determinants of acidic pH-dependent transport of human equilibrative nucleoside transporter 3","volume":"292","author":"Rahman","year":"2017","journal-title":"The Journal of Biological Chemistry"},{"key":"10.1016\/j.pharmthera.2022.108300_bb1390","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12113206","article-title":"\u201cOpen Sesame?\u201d: Biomarker status of the human equilibrative nucleoside transporter-1 and molecular mechanisms influencing its expression and activity in the uptake and cytotoxicity of gemcitabine in pancreatic cancer","volume":"12","author":"Randazzo","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.pharmthera.2022.108300_bb1395","doi-asserted-by":"crossref","first-page":"4383","DOI":"10.4049\/jimmunol.175.7.4383","article-title":"Gs protein-coupled adenosine receptor signaling and lytic function of activated NK cells","volume":"175","author":"Raskovalova","year":"2005","journal-title":"Journal of Immunology"},{"key":"10.1016\/j.pharmthera.2022.108300_bb1400","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1385\/IR:36:1:91","article-title":"Adenosine-mediated inhibition of cytotoxic activity and cytokine production by IL-2\/NKp46-activated NK cells: Involvement of protein kinase A isozyme I (PKA I)","volume":"36","author":"Raskovalova","year":"2006","journal-title":"Immunologic Research"},{"key":"10.1016\/j.pharmthera.2022.108300_bb1405","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.jconrel.2007.08.018","article-title":"A new nanomedicine of gemcitabine displays enhanced anticancer activity in sensitive and resistant leukemia types","volume":"124","author":"Reddy","year":"2007","journal-title":"Journal of Controlled Release"},{"key":"10.1016\/j.pharmthera.2022.108300_bb1410","doi-asserted-by":"crossref","first-page":"H859","DOI":"10.1152\/ajpheart.00251.2002","article-title":"A1 adenosine receptor overexpression attenuates ischemia-reperfusion-induced apoptosis and caspase 3 activity","volume":"284","author":"Regan","year":"2003","journal-title":"American Journal of Physiology. Heart and Circulatory Physiology"},{"key":"10.1016\/j.pharmthera.2022.108300_bb1415","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1016\/j.ccr.2014.05.016","article-title":"Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy","volume":"25","author":"Ries","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1016\/j.pharmthera.2022.108300_bb1420","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1080\/09687680010026313","volume":"18","author":"Ritzel","year":"2001","journal-title":"Molecular Membrane Biology"},{"key":"10.1016\/j.pharmthera.2022.108300_bb1425","doi-asserted-by":"crossref","first-page":"2914","DOI":"10.1074\/jbc.M007746200","article-title":"Molecular identification and characterization of novel human and mouse concentrative Na+\u2212nucleoside cotransporter proteins (hCNT3 and mCNT3) broadly selective for purine and pyrimidine nucleosides (system cib)","volume":"276","author":"Ritzel","year":"2001","journal-title":"The Journal of Biological Chemistry"},{"key":"10.1016\/j.pharmthera.2022.108300_bb1430","doi-asserted-by":"crossref","first-page":"H771","DOI":"10.1152\/ajpheart.00711.2009","article-title":"Equilibrative nucleoside transporter 1 plays an essential role in cardioprotection","volume":"298","author":"Rose","year":"2010","journal-title":"American Journal of Physiology. Heart and Circulatory Physiology"},{"key":"10.1016\/j.pharmthera.2022.108300_bb1435","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1038\/nature08144","article-title":"The structure and function of G-protein-coupled receptors","volume":"459","author":"Rosenbaum","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2022.108300_bb1440","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.ccell.2015.02.015","article-title":"Macrophages and therapeutic resistance in cancer","volume":"27","author":"Ruffell","year":"2015","journal-title":"Cancer Cell"},{"key":"10.1016\/j.pharmthera.2022.108300_bb1445","doi-asserted-by":"crossref","first-page":"6120","DOI":"10.4049\/jimmunol.1101225","article-title":"Adenosinergic regulation of the expansion and immunosuppressive activity of CD11b+Gr1+ cells","volume":"187","author":"Ryzhov","year":"2011","journal-title":"Journal of Immunology"},{"key":"10.1016\/j.pharmthera.2022.108300_bb1450","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.jsps.2012.05.011","article-title":"Adenosine and its receptors as therapeutic targets: An overview","volume":"21","author":"Sachdeva","year":"2013","journal-title":"Saudi Pharmaceutical Journal"},{"key":"10.1016\/j.pharmthera.2022.108300_bb1455","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1038\/ni1193","article-title":"Egr-2 and Egr-3 are negative regulators of T cell activation","volume":"6","author":"Safford","year":"2005","journal-title":"Nature Immunology"},{"key":"10.1016\/j.pharmthera.2022.108300_bb1460","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1093\/intimm\/dxh195","article-title":"Differential effect of insulin and elevated glucose level on adenosine transport in rat B lymphocytes","volume":"17","author":"Sakowicz","year":"2005","journal-title":"International Immunology"},{"key":"10.1016\/j.pharmthera.2022.108300_bb1465","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.4049\/jimmunol.145.7.2235","article-title":"Fc gamma receptor-mediated functions in neutrophils are modulated by adenosine receptor occupancy. A1 receptors are stimulatory and A2 receptors are inhibitory","volume":"145","author":"Salmon","year":"1990","journal-title":"Journal of Immunology"},{"key":"10.1016\/j.pharmthera.2022.108300_bb1470","doi-asserted-by":"crossref","first-page":"4429","DOI":"10.1074\/jbc.275.6.4429","article-title":"Disruption of the A(3) adenosine receptor gene in mice and its effect on stimulated inflammatory cells","volume":"275","author":"Salvatore","year":"2000","journal-title":"The Journal of Biological Chemistry"},{"key":"10.1016\/j.pharmthera.2022.108300_bb1475","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1053\/gast.2000.16502","article-title":"Activation of adenosine A1-receptor pathway induces edema formation in the pancreas of rats","volume":"119","author":"Satoh","year":"2000","journal-title":"Gastroenterology"},{"key":"10.1016\/j.pharmthera.2022.108300_bb1480","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1182\/blood-2013-02-482406","article-title":"Adenosine production by human B cells and B cell-mediated suppression of activated T cells","volume":"122","author":"Saze","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2022.108300_bb1485","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1182\/blood-2003-06-1959","article-title":"Role of adenosine receptors in regulating chemotaxis and cytokine production of plasmacytoid dendritic cells","volume":"103","author":"Schnurr","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2022.108300_bb1490","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/0304-4165(68)90297-3","article-title":"Studies on the uptake of nucleic acid precursors into cells in tissue culture","volume":"158","author":"Scholtissek","year":"1968","journal-title":"Biochimica et Biophysica Acta"},{"key":"10.1016\/j.pharmthera.2022.108300_bb1495","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1124\/mol.58.3.477","article-title":"Human adenosine A(1), A(2A), A(2B), and A(3) receptors expressed in Chinese hamster ovary cells all mediate the phosphorylation of extracellular-regulated kinase 1\/2","volume":"58","author":"Schulte","year":"2000","journal-title":"Molecular Pharmacology"},{"key":"10.1016\/j.pharmthera.2022.108300_bb1500","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1021\/bi015833w","article-title":"A single glycine mutation in the equilibrative nucleoside transporter gene, hENT1, alters nucleoside transport activity and sensitivity to nitrobenzylthioinosine","volume":"41","author":"SenGupta","year":"2002","journal-title":"Biochemistry"},{"key":"10.1016\/j.pharmthera.2022.108300_bb1505","doi-asserted-by":"crossref","first-page":"5164","DOI":"10.18632\/oncotarget.3286","article-title":"Targeting EGF-receptor(s) - STAT1 axis attenuates tumor growth and metastasis through downregulation of MUC4 mucin in human pancreatic cancer","volume":"6","author":"Seshacharyulu","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.pharmthera.2022.108300_bb1510","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0053814","article-title":"Sleep-wake sensitive mechanisms of adenosine release in the basal forebrain of rodents: an in vitro study","volume":"8","author":"Sims","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.pharmthera.2022.108300_bb1515","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.it.2008.12.002","article-title":"T regulatory cells: Hypoxia-adenosinergic suppression and re-direction of the immune response","volume":"30","author":"Sitkovsky","year":"2009","journal-title":"Trends in Immunology"},{"key":"10.1016\/j.pharmthera.2022.108300_bb1520","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1038\/onc.2012.179","article-title":"The MUC4 mucin mediates gemcitabine resistance of human pancreatic cancer cells via the concentrative nucleoside transporter family","volume":"32","author":"Skrypek","year":"2013","journal-title":"Oncogene"},{"key":"10.1016\/j.pharmthera.2022.108300_bb1525","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.ijpharm.2011.02.037","article-title":"In vitro and in vivo anti-tumor activities of a gemcitabine derivative carried by nanoparticles","volume":"409","author":"Sloat","year":"2011","journal-title":"International Journal of Pharmaceutics"},{"key":"10.1016\/j.pharmthera.2022.108300_bb1530","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1002\/jlb.67.3.345","article-title":"Nitric oxide regulates nucleoside transport in activated B lymphocytes","volume":"67","author":"Soler","year":"2000","journal-title":"Journal of Leukocyte Biology"},{"key":"10.1016\/j.pharmthera.2022.108300_bb1535","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1042\/bj20030260","article-title":"Interferon-gamma regulates nucleoside transport systems in macrophages through signal transduction and activator of transduction factor 1 (STAT1)-dependent and -independent signalling pathways","volume":"375","author":"Soler","year":"2003","journal-title":"The Biochemical Journal"},{"key":"10.1016\/j.pharmthera.2022.108300_bb1540","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1096\/fj.01-0022com","article-title":"Macrophages require different nucleoside transport systems for proliferation and activation","volume":"15","author":"Soler","year":"2001","journal-title":"The FASEB Journal"},{"key":"10.1016\/j.pharmthera.2022.108300_bb1545","doi-asserted-by":"crossref","first-page":"30043","DOI":"10.1074\/jbc.M101807200","article-title":"Lipopolysaccharide-induced apoptosis of macrophages determines the up-regulation of concentrative nucleoside transporters Cnt1 and Cnt2 through tumor necrosis factor-alpha-dependent and -independent mechanisms","volume":"276","author":"Soler","year":"2001","journal-title":"The Journal of Biological Chemistry"},{"key":"10.1016\/j.pharmthera.2022.108300_bb1550","doi-asserted-by":"crossref","DOI":"10.1177\/1759091414543439","article-title":"Role of the intracellular nucleoside transporter ENT3 in transmitter and high K+ stimulation of astrocytic ATP release investigated using siRNA against ENT3","volume":"6","author":"Song","year":"2014","journal-title":"ASN Neuro"},{"key":"10.1016\/j.pharmthera.2022.108300_bb1555","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.3389\/fimmu.2019.02465","article-title":"Expression of CD39 is correlated with HIV DNA levels in naive tregs in Chronically infected ART naive patients","volume":"10","author":"Song","year":"2019","journal-title":"Frontiers in Immunology"},{"key":"10.1016\/j.pharmthera.2022.108300_bb1560","doi-asserted-by":"crossref","first-page":"27478","DOI":"10.18632\/oncotarget.4393","article-title":"Myeloid-derived suppressor cells contribute to A2B adenosine receptor-induced VEGF production and angiogenesis in a mouse melanoma model","volume":"6","author":"Sorrentino","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.pharmthera.2022.108300_bb1565","doi-asserted-by":"crossref","first-page":"6956","DOI":"10.1158\/1078-0432.CCR-04-0224","article-title":"The absence of human equilibrative nucleoside transporter 1 is associated with reduced survival in patients with gemcitabine-treated pancreas adenocarcinoma","volume":"10","author":"Spratlin","year":"2004","journal-title":"Clinical Cancer Research"},{"key":"10.1016\/j.pharmthera.2022.108300_bb1570","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1093\/carcin\/bgr223","article-title":"MicroRNA-150 directly targets MUC4 and suppresses growth and malignant behavior of pancreatic cancer cells","volume":"32","author":"Srivastava","year":"2011","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.pharmthera.2022.108300_bb1575","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/s41375-019-0497-6","article-title":"Loss of KDM6A confers drug resistance in acute myeloid leukemia","volume":"34","author":"Stief","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.pharmthera.2022.108300_bb1580","doi-asserted-by":"crossref","DOI":"10.3390\/molecules22040676","article-title":"Adenosine A1 and A2A receptors in the brain: Current research and their role in neurodegeneration","volume":"22","author":"Stockwell","year":"2017","journal-title":"Molecules"},{"key":"10.1016\/j.pharmthera.2022.108300_bb1585","doi-asserted-by":"crossref","DOI":"10.3390\/molecules26175354","article-title":"Contribution of the adenosine 2A receptor to behavioral effects of tetrahydrocannabinol, cannabidiol and PECS-101","volume":"26","author":"Stollenwerk","year":"2021","journal-title":"Molecules"},{"key":"10.1016\/j.pharmthera.2022.108300_bb1590","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.ejca.2017.08.033","article-title":"Potential role of polymorphisms in the transporter genes ENT1 and MATE1\/OCT2 in predicting TAS-102 efficacy and toxicity in patients with refractory metastatic colorectal cancer","volume":"86","author":"Suenaga","year":"2017","journal-title":"European Journal of Cancer"},{"key":"10.1016\/j.pharmthera.2022.108300_bb1595","first-page":"1372","article-title":"Mucins in pancreatic cancer: biological role, implications in carcinogenesis and applications in diagnosis and therapy","volume":"7","author":"Suh","year":"2017","journal-title":"American Journal of Cancer Research"},{"key":"10.1016\/j.pharmthera.2022.108300_bb1600","article-title":"Adenosine-A2A Receptor Pathway in Cancer Immunotherapy","volume":"13","author":"Sun","year":"2022","journal-title":"Frontiers in Immunology"},{"key":"10.1016\/j.pharmthera.2022.108300_bb1605","doi-asserted-by":"crossref","first-page":"21519","DOI":"10.1074\/jbc.273.34.21519","article-title":"Chimeric constructs between human and rat equilibrative nucleoside transporters (hENT1 and rENT1) reveal hENT1 structural domains interacting with coronary vasoactive drugs","volume":"273","author":"Sundaram","year":"1998","journal-title":"The Journal of Biological Chemistry"},{"key":"10.1016\/j.pharmthera.2022.108300_bb1610","doi-asserted-by":"crossref","first-page":"584","DOI":"10.4103\/ijmr.IJMR_2047_17","article-title":"Need for alternatives to animals in experimentation: An Indian perspective","volume":"149","author":"Swaminathan","year":"2019","journal-title":"The Indian Journal of Medical Research"},{"key":"10.1016\/j.pharmthera.2022.108300_bb1615","doi-asserted-by":"crossref","first-page":"C1991","DOI":"10.1152\/ajpcell.2001.281.6.C1991","article-title":"Regulation of K(+) current in human airway epithelial cells by exogenous and autocrine adenosine","volume":"281","author":"Szkotak","year":"2001","journal-title":"American Journal of Physiology. Cell Physiology"},{"key":"10.1016\/j.pharmthera.2022.108300_bb1620","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1093\/jb\/mvh180","article-title":"Gene-expression profiling reveals down-regulation of equilibrative nucleoside transporter 1 (ENT1) in Ara-C-resistant CCRF-CEM-derived cells","volume":"136","author":"Takagaki","year":"2004","journal-title":"Journal of Biochemistry"},{"key":"10.1016\/j.pharmthera.2022.108300_bb1625","doi-asserted-by":"crossref","first-page":"13555","DOI":"10.1038\/s41598-019-49929-w","article-title":"Bidirectional transport of 2-chloroadenosine by equilibrative nucleoside transporter 4 (hENT4): Evidence for allosteric kinetics at acidic pH","volume":"9","author":"Tandio","year":"2019","journal-title":"Scientific Reports"},{"key":"10.1016\/j.pharmthera.2022.108300_bb1630","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1111\/his.12607","article-title":"High numbers of macrophages, especially M2-like (CD163-positive), correlate with hyaluronan accumulation and poor outcome in breast cancer","volume":"66","author":"Tiainen","year":"2015","journal-title":"Histopathology"},{"key":"10.1016\/j.pharmthera.2022.108300_bb1635","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.2174\/13816128112092472","article-title":"Mucin-based targeted pancreatic cancer therapy","volume":"18","author":"Torres","year":"2012","journal-title":"Current Pharmaceutical Design"},{"key":"10.1016\/j.pharmthera.2022.108300_bb1640","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1152\/physrev.00031.2005","article-title":"Adenosine and kidney function","volume":"86","author":"Vallon","year":"2006","journal-title":"Physiological Reviews"},{"key":"10.1016\/j.pharmthera.2022.108300_bb1645","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1016\/S0026-895X(24)26507-X","article-title":"[(3)H]MRE 3008F20: A novel antagonist radioligand for the pharmacological and biochemical characterization of human A(3) adenosine receptors","volume":"57","author":"Varani","year":"2000","journal-title":"Molecular Pharmacology"},{"key":"10.1016\/j.pharmthera.2022.108300_bb1650","doi-asserted-by":"crossref","first-page":"925","DOI":"10.3389\/fimmu.2019.00925","article-title":"Targeting adenosine in cancer immunotherapy to enhance T-cell function","volume":"10","author":"Vigano","year":"2019","journal-title":"Frontiers in Immunology"},{"key":"10.1016\/j.pharmthera.2022.108300_bb1655","doi-asserted-by":"crossref","first-page":"113747","DOI":"10.1016\/j.bcp.2019.113747","article-title":"Affinity, binding kinetics and functional characterization of draflazine analogues for human equilibrative nucleoside transporter 1 (SLC29A1)","volume":"172","author":"Vlachodimou","year":"2020","journal-title":"Biochemical Pharmacology"},{"key":"10.1016\/j.pharmthera.2022.108300_bb1660","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1111\/j.1742-4658.2008.06793.x","article-title":"Membrane compartments and purinergic signalling: The purinome, a complex interplay among ligands, degrading enzymes, receptors and transporters","volume":"276","author":"Volonte","year":"2009","journal-title":"The FEBS Journal"},{"key":"10.1016\/j.pharmthera.2022.108300_bb1665","doi-asserted-by":"crossref","first-page":"3853","DOI":"10.1113\/jphysiol.2013.253450","article-title":"Neuronal transporter and astrocytic ATP exocytosis underlie activity-dependent adenosine release in the hippocampus","volume":"591","author":"Wall","year":"2013","journal-title":"The Journal of Physiology"},{"key":"10.1016\/j.pharmthera.2022.108300_bb1670","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.bioorg.2018.01.004","article-title":"Benzopyrone represents a privilege scaffold to identify novel adenosine A1\/A2A receptor antagonists","volume":"77","author":"van der Walt","year":"2018","journal-title":"Bioorganic Chemistry"},{"key":"10.1016\/j.pharmthera.2022.108300_bb1675","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1016\/j.bcp.2013.08.063","article-title":"Dipyridamole analogs as pharmacological inhibitors of equilibrative nucleoside transporters. Identification of novel potent and selective inhibitors of the adenosine transporter function of human equilibrative nucleoside transporter 4 (hENT4)","volume":"86","author":"Wang","year":"2013","journal-title":"Biochemical Pharmacology"},{"key":"10.1016\/j.pharmthera.2022.108300_bb1680","first-page":"3171","article-title":"Enhanced efficacy of gemcitabine by indole-3-carbinol in pancreatic cell lines: The role of human equilibrative nucleoside transporter 1","volume":"31","author":"Wang","year":"2011","journal-title":"Anticancer Research"},{"key":"10.1016\/j.pharmthera.2022.108300_bb1685","doi-asserted-by":"crossref","first-page":"3834","DOI":"10.1021\/acs.jmedchem.9b01237","article-title":"The druggability of solute carriers","volume":"63","author":"Wang","year":"2020","journal-title":"Journal of Medicinal Chemistry"},{"key":"10.1016\/j.pharmthera.2022.108300_bb1690","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.4161\/auto.25873","article-title":"Autophagy-dependent ATP release from dying cells via lysosomal exocytosis","volume":"9","author":"Wang","year":"2013","journal-title":"Autophagy"},{"key":"10.1016\/j.pharmthera.2022.108300_bb1695","doi-asserted-by":"crossref","first-page":"11484","DOI":"10.1039\/D1SC02295D","article-title":"Influence of stereochemistry on the activity of rapadocin, an isoform-specific inhibitor of the nucleoside transporter ENT1","volume":"12","author":"Wang","year":"2021","journal-title":"Chemical Science"},{"key":"10.1016\/j.pharmthera.2022.108300_bb1700","doi-asserted-by":"crossref","first-page":"8375","DOI":"10.1074\/jbc.275.12.8375","volume":"275","author":"Ward","year":"2000","journal-title":"The Journal of Biological Chemistry"},{"key":"10.1016\/j.pharmthera.2022.108300_bb1705","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1158\/1535-7163.MCT-20-0316","article-title":"EMT-induced gemcitabine resistance in pancreatic cancer involves the functional loss of equilibrative nucleoside transporter 1","volume":"20","author":"Weadick","year":"2021","journal-title":"Molecular Cancer Therapeutics"},{"key":"10.1016\/j.pharmthera.2022.108300_bb1710","doi-asserted-by":"crossref","first-page":"2330","DOI":"10.1016\/j.celrep.2018.04.077","article-title":"Equilibrative nucleoside transporter 3 regulates T cell homeostasis by coordinating lysosomal function with nucleoside availability","volume":"23","author":"Wei","year":"2018","journal-title":"Cell Reports"},{"key":"10.1016\/j.pharmthera.2022.108300_bb1715","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1002\/(SICI)1097-4644(1997)28\/29+<111::AID-JCB12>3.0.CO;2-K","article-title":"Dose-ranging study of indole-3-carbinol for breast cancer prevention","volume":"28\u201329","author":"Wong","year":"1997","journal-title":"Journal of Cellular Biochemistry. Supplement"},{"key":"10.1016\/j.pharmthera.2022.108300_bb1720","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jconrel.2013.03.033","article-title":"Just getting into cells is not enough: mechanisms underlying 4-(N)-stearoyl gemcitabine solid lipid nanoparticle\u2019s ability to overcome gemcitabine resistance caused by RRM1 overexpression","volume":"169","author":"Wonganan","year":"2013","journal-title":"Journal of Controlled Release"},{"key":"10.1016\/j.pharmthera.2022.108300_bb1725","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1007\/s00280-008-0829-0","article-title":"Intracellular disposition of fludarabine triphosphate in human natural killer cells","volume":"63","author":"Woodahl","year":"2009","journal-title":"Cancer Chemotherapy and Pharmacology"},{"key":"10.1016\/j.pharmthera.2022.108300_bb1730","doi-asserted-by":"crossref","first-page":"e3000161","DOI":"10.1371\/journal.pbio.3000161","article-title":"Physiology and effects of nucleosides in mice lacking all four adenosine receptors","volume":"17","author":"Xiao","year":"2019","journal-title":"PLoS Biology"},{"key":"10.1016\/j.pharmthera.2022.108300_bb1735","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1126\/science.1202793","article-title":"Structure of an agonist-bound human A2A adenosine receptor","volume":"332","author":"Xu","year":"2011","journal-title":"Science"},{"key":"10.1016\/j.pharmthera.2022.108300_bb1740","doi-asserted-by":"crossref","first-page":"350","DOI":"10.3109\/21691401.2014.951722","article-title":"Paclitaxel-loaded stealth liposomes: Development, characterization, pharmacokinetics, and biodistribution","volume":"44","author":"Xu","year":"2016","journal-title":"Artificial Cells, Nanomedicine, and Biotechnology"},{"key":"10.1016\/j.pharmthera.2022.108300_bb1745","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1097\/FJC.0000000000000194","article-title":"Equilibrative nucleoside transporters 1 and 4: which one is a better target for cardioprotection against ischemia-reperfusion injury?","volume":"65","author":"Yang","year":"2015","journal-title":"Journal of Cardiovascular Pharmacology"},{"key":"10.1016\/j.pharmthera.2022.108300_bb1750","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/j.bbamcr.2008.01.024","article-title":"Nucleotide- and nucleoside-converting ectoenzymes: Important modulators of purinergic signalling cascade","volume":"1783","author":"Yegutkin","year":"2008","journal-title":"Biochimica et Biophysica Acta"},{"key":"10.1016\/j.pharmthera.2022.108300_bb1755","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1242\/jcs.03389","article-title":"Wound-induced ATP release and EGF receptor activation in epithelial cells","volume":"120","author":"Yin","year":"2007","journal-title":"Journal of Cell Science"},{"key":"10.1016\/j.pharmthera.2022.108300_bb1760","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1213\/01.ANE.0000180994.10087.6F","article-title":"Antinociception of intrathecal adenosine receptor subtype agonists in rat formalin test","volume":"101","author":"Yoon","year":"2005","journal-title":"Anesthesia and Analgesia"},{"key":"10.1016\/j.pharmthera.2022.108300_bb1765","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1158\/0008-5472.CAN-17-2826","article-title":"A2AR adenosine signaling suppresses natural killer cell maturation in the tumor microenvironment","volume":"78","author":"Young","year":"2018","journal-title":"Cancer Research"},{"key":"10.1016\/j.pharmthera.2022.108300_bb1770","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.mam.2012.05.007","article-title":"The human concentrative and equilibrative nucleoside transporter families, SLC28 and SLC29","volume":"34","author":"Young","year":"2013","journal-title":"Molecular Aspects of Medicine"},{"key":"10.1016\/j.pharmthera.2022.108300_bb1775","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1080\/00498250801927427","article-title":"Human equilibrative nucleoside transporter (ENT) family of nucleoside and nucleobase transporter proteins","volume":"38","author":"Young","year":"2008","journal-title":"Xenobiotica"},{"key":"10.1016\/j.pharmthera.2022.108300_bb1780","doi-asserted-by":"crossref","first-page":"12196","DOI":"10.1021\/acs.jmedchem.0c00237","article-title":"Adenosine A2A receptor antagonists for cancer immunotherapy","volume":"63","author":"Yu","year":"2020","journal-title":"Journal of Medicinal Chemistry"},{"key":"10.1016\/j.pharmthera.2022.108300_bb1785","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.bcp.2019.03.032","article-title":"Long residence time adenosine A1 receptor agonists produce sustained wash-resistant antilipolytic effect in rat adipocytes","volume":"164","author":"Yun","year":"2019","journal-title":"Biochemical Pharmacology"},{"key":"10.1016\/j.pharmthera.2022.108300_bb1790","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1139\/Y09-075","article-title":"N-methyl-D-aspartate-evoked adenosine and inosine release from neurons requires extracellular calcium","volume":"87","author":"Zamzow","year":"2009","journal-title":"Canadian Journal of Physiology and Pharmacology"},{"key":"10.1016\/j.pharmthera.2022.108300_bb1795","doi-asserted-by":"crossref","first-page":"59950","DOI":"10.18632\/oncotarget.19048","article-title":"The molecular mechanisms of chemoresistance in cancers","volume":"8","author":"Zheng","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.pharmthera.2022.108300_bb1800","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/nature16064","article-title":"Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer","volume":"527","author":"Zheng","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2022.108300_bb1805","doi-asserted-by":"crossref","first-page":"7432","DOI":"10.1073\/pnas.89.16.7432","article-title":"Molecular cloning and characterization of an adenosine receptor: the A3 adenosine receptor","volume":"89","author":"Zhou","year":"1992","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.pharmthera.2022.108300_bb1810","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/B978-0-12-420067-8.00022-2","article-title":"Preparation of fatty acid micelles","volume":"533","author":"Zhu","year":"2013","journal-title":"Methods in Enzymology"},{"key":"10.1016\/j.pharmthera.2022.108300_bb1815","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.febslet.2008.12.041","article-title":"Identification of a novel point mutation in ENT1 that confers resistance to Ara-C in human T cell leukemia CCRF-CEM cells","volume":"583","author":"Zimmerman","year":"2009","journal-title":"FEBS Letters"},{"key":"10.1016\/j.pharmthera.2022.108300_bb1820","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/j.neuint.2007.09.004","article-title":"ATP and acetylcholine, equal brethren","volume":"52","author":"Zimmermann","year":"2008","journal-title":"Neurochemistry International"},{"key":"10.1016\/j.pharmthera.2022.108300_bb1825","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1111\/j.1478-3231.2005.01033.x","article-title":"Hepatobiliary transporter expression in human hepatocellular carcinoma","volume":"25","author":"Zollner","year":"2005","journal-title":"Liver International"}],"container-title":["Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725822001942?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725822001942?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T22:31:29Z","timestamp":1759012289000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163725822001942"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":363,"alternative-id":["S0163725822001942"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmthera.2022.108300","relation":{},"ISSN":["0163-7258"],"issn-type":[{"value":"0163-7258","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nucleoside transporters and immunosuppressive adenosine signaling in the tumor microenvironment: Potential therapeutic opportunities","name":"articletitle","label":"Article Title"},{"value":"Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharmthera.2022.108300","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"108300"}}